BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 1 CLINICAL STUDY PROTOCOL 
 
  
Protocol Title:  A Phase 2, Randomized, Double-Blind, Placebo-Controlled 
Study to Evaluate the Efficacy and Safety of SARS-CoV-2 
Neutralizing Antibody BGB-DXP593 in Patients With Mild to 
Moderate COVID-19 
Protocol Identifier: BGB-DXP593-102 
Phase: 2 
Investigational Products: BGB-DXP593 
Placebo 
Proposed Indication: COVID-19 
Sponsor: BeiGene, Ltd. c/o BeiGene USA, Inc. 2955 Campus Drive, Suite 200 San Mateo, California 94403 USA 
Sponsor Medical Monitor: 
Original Protocol Version 0.0: 14 August 2020 
Amendment 1.0 03 September 2020 
Amendment 2.0 27 October 2020 
 
 
 
  
Confidentiality Statement 
This Document Is Not for Distribution ‚Äì Do Not Copy 
This document contains confidential information and is the proprietary property of BeiGene, Ltd., and its 
subsidiaries. This document is for use by individuals and their designated representatives for their 
confidential review, consideration, and/or participation in investigational trial(s). This document may not be copied or distributed for review by any unauthoriz ed individuals without the prior written authorization 
of BeiGene, Ltd., or one of its subsidiaries. Your acceptance of this document constitutes agreement that you will not disclose the information contained herein to others without prior written authorization from 
BeiGene, Ltd., or one of its subsidiaries. 
Version .0 VV-CLIN-073998 1

BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 3 INVESTIGATOR SIGNATURE PAGE 
 
Protocol Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to 
Evaluate the Efficacy and Safety of SARS-CoV-2 Neutralizing 
Antibody BGB-DXP593 in Patients With Mild to Moderate 
COVID-19 
 
Protocol Identifier: BGB-DXP593-102 
 
This protocol is a confidential communication of BeiGene, Ltd., and its subsidiaries. I confirm 
that I have read this protocol, I understand it, and I will work according to this protocol and the 
terms of the clinical study agreement governing the study. I will also work consistently with the 
ethical principles that have their origin in the Declaration of Helsinki and that are consistent with 
good clinical practices and the a pplicable laws and regulations . Acceptance of this document 
constitutes my agreement that no unpublished inform ation contained herein will be published or 
disclosed without prior written approval from BeiGene, Ltd., or one of its subsidiaries. 
 
Instructions for Investigator:  Please SIGN and DATE this signature page prior to 
implementation of this sponsor-approved prot ocol. PRINT your name, title, and the name 
and address of the center in wh ich the study will be conducted.  
 I have read this protocol in its entiret y and agree to conduct the study accordingly: 
 Signature of Investigator: _______________________________ Date: _____________ 
Printed Name: _______________________________ 
Investigator Title: _______________________________ Name/Address of Center: _______________________________ 
 _______________________________ 
 _______________________________  _______________________________ 
 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 4 TABLE OF CONTENTS 
FINAL PROTOCOL APPROVAL SHEET ................................................................................. 2  
INVESTIGATOR SIGNATURE PAGE...................................................................................... 3  
TABLE OF CONTENTS ............................................................................................................ 4 
LIST OF TABLES ................................................................................................................ ...... 9  
LIST OF FIGURES ............................................................................................................... ..... 9  
SYNOPSIS  ..................................................................................................................... .......... 10  
LIST OF ABBREVIATIONS AND TERMS ............................................................................ 14  
1. INTRODUCTION AND RATIONALES ................................................................ 16  
1.1. Introductio n ............................................................................................................ 16 
1.2. BGB-DXP593 as a SARS-CoV-2 Neut ralizing Monocl onal Anti body .................... 16  
1.2.1.  Nonclinical ............................................................................................................. 16  
1.2.2.  Clinical Experience................................................................................................. 18  
1.3. Study Rationa le ...................................................................................................... 18 
1.3.1.  Rationale for Selection of BGB-DXP593 Doses ..................................................... 19 
1.3.2.  Rationale for Pharmacokinetic Sampling ................................................................ 20  
1.3.3.  Rationale for Biomarker Strategy ............................................................................ 21  
1.4. Benefit-Risk Assessment ........................................................................................ 21  
1.5. Study Conduc t ........................................................................................................ 22 
2. STUDY OBJECTIVES AND ENDPOINTS ........................................................... 23  
2.1. Study Objec tives ..................................................................................................... 23 
2.1.1.  Primary Objective ................................................................................................... 23  
2.1.2.  Secondary Obj ectives  ............................................................................................. 23  
2.1.3.  Exploratory Objective ............................................................................................. 23  
2.2. Study Endpoi nts ..................................................................................................... 23 
2.2.1.  Primary E ndpoint .................................................................................................... 23 
2.2.2.  Secondary E ndpoints .............................................................................................. 23  
2.2.3.  Exploratory E ndpoints ............................................................................................ 24  
3. STUDY DESIGN ................................................................................................... 25  
3.1. Summary of Study Design ...................................................................................... 25  
4. STUDY POPULATION ......................................................................................... 27  
4.1. Inclusion Criteria .................................................................................................... 27  
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 5 4.2. Exclusion Criteria ................................................................................................... 27  
5. STUDY TREATMENT .......................................................................................... 30  
5.1. Formulation, Packaging, and Handling ................................................................... 30  
5.1.1.  BGB-DXP593 ........................................................................................................ 30 
5.1.2.  Placebo ................................................................................................................... 30  
5.2. Dosage, Administration, and Compliance ............................................................... 30  
5.3. Incorrect Administration ......................................................................................... 31  
5.4. Dose Interruption or Modification........................................................................... 31  
5.5. Blinding.................................................................................................................. 31  
5.5.1.  Emergency Unblinding ........................................................................................... 32  
5.5.2.  Inadvertent Unblinding ........................................................................................... 32  
6. PRIOR AND CONCOMITANT THERAPY .......................................................... 33  
6.1. Permitted Concomitant Medi cations/Proce dures ..................................................... 33  
6.2. Prohibited Concomitant Me dications/Pro cedures .................................................... 33  
6.3. Potential Interactions  Between the Study Drug and Concomitant 
Medications ............................................................................................................ 33  
7. STUDY PERIODS, VISITS, OR PROCEDURES .................................................. 34  
7.1. Screening Period ..................................................................................................... 34  
7.1.1.  Informed Consent a nd Screening Log ..................................................................... 34  
7.1.2.  Patient Numbering .................................................................................................. 34  
7.2. Enrollment  .............................................................................................................. 34  
7.2.1.  Confirmation of  Eligib ility...................................................................................... 34  
7.2.2.  Enrollment/Rando mizatio n ..................................................................................... 34  
7.3. Treatment ............................................................................................................... 34  
7.4. Follow-up Period .................................................................................................... 35  
7.4.1.  End-of-Study Visit .................................................................................................. 35  
7.4.2.  Safety Follow-up Visit After Premature Study Discontinuation .............................. 35  
7.4.3.  Lost to Follow-up ................................................................................................... 35  
7.5. Discontinuation From Study Treatme nt or From th e Study ..................................... 35  
7.5.1.  Patient Discontinuation From Study Treatment ....................................................... 35  
7.5.2.  Patient Discontinuation From the Study (End of Study for an Individual 
Patient) ................................................................................................................... 36  
7.6. End of Study ........................................................................................................... 36  
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 6 8. STUDY ASSESSMENTS ....................................................................................... 37  
8.1. Screening Assessments ........................................................................................... 37  
8.1.1.  Demographic Data, Medical History, and Prior Medications ................................... 37  
8.1.2.  Review of SARS-CoV-2 Test Result ...................................................................... 37  
8.2. Safety Assessments................................................................................................. 37  
8.2.1.  Vital Signs .............................................................................................................. 37  
8.2.2.  Physical Examinations ............................................................................................ 38  
8.2.3.  Laboratory Safety Tests .......................................................................................... 38  
8.2.4.  Electrocardiograms ................................................................................................. 38  
8.2.5.  Adverse Events ....................................................................................................... 38  
8.3. Efficacy Assessment ............................................................................................... 39  
8.3.1.  Viral Load .............................................................................................................. 39  
8.3.2.  WHO 8-Point Ordinal Scale.................................................................................... 39  
8.3.3.  COVID-19-Related Symptoms and Disease Severity .............................................. 40  
8.4. Pharmacokinetic Assessment and Antidrug Antibody Testing ................................. 41  
8.5. Biomarkers ............................................................................................................. 41  
8.6. Visit Wi ndows ........................................................................................................ 42 
8.7. Unscheduled Visits ................................................................................................. 42  
9. SAFETY MONITORING AND REPORTING ....................................................... 43  
9.1. Risks Associated W ith BGB-DX P593 .................................................................... 43 
9.2. General Plan to Manage Safety Concerns ............................................................... 43  
9.2.1.  Eligibility Cr iteria ................................................................................................... 43  
9.2.2.  Safety Monitoring Plan ........................................................................................... 43  
9.3. Adverse Events ....................................................................................................... 44  
9.3.1.  Definitions and Reporting ....................................................................................... 44  
9.3.2.  Assessment of Severity ........................................................................................... 44  
9.3.3.  Assessment of Causality  ......................................................................................... 45  
9.3.4.  Follow-up of Adverse Events .................................................................................. 46  
9.3.5.  Laboratory Test Abnormalitie s ............................................................................... 46  
9.4. Definition of a Serious  Adverse Event .................................................................... 47  
9.5. Suspected Unexpected Serious Adverse Reaction ................................................... 48  
9.6. Timing, Frequency, and Method of Ca pturing Adverse Events and Serious 
Adverse Events ....................................................................................................... 48  
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 7 9.6.1.  Adverse Event Recording Period ............................................................................ 48  
9.6.2.  Reporting Serious Adverse Events .......................................................................... 48  
9.6.3.  Eliciting Adverse Events......................................................................................... 49  
9.6.4.  Deaths .................................................................................................................... 49  
9.6.5.  Recording Pregnancies ........................................................................................... 49  
9.6.6.  Expedited Reporting to Health Authorities, Investigators, Institutional 
Review Boards, and Indepe ndent Ethics Committees  .............................................. 50  
9.6.7.  Recording Infusion-Related Reactions .................................................................... 50  
9.7. Management of Infusion-Related Reac tions and Severe Hypersens itivity ................ 50  
9.7.1.  Managing Infusion-Related Reactions .................................................................... 50  
9.7.2.  Severe Hypersensitiv ity Reacti ons .......................................................................... 51  
10. STATISTICAL METHODS AND SAMPLE SIZE DETERMINATION ................ 53  
10.1.  Statistical Analysis ................................................................................................. 53  
10.1.1.  Analysis Sets .......................................................................................................... 53  
10.1.2.  Randomization Methods  ......................................................................................... 53  
10.1.3.  Patient Disposition .................................................................................................. 53  
10.1.4.  Demographic and Other Baseline Characteristics .................................................... 53  
10.1.5.  Prior and Concomitant  Medications ........................................................................ 54  
10.2.  Efficacy Analyses ................................................................................................... 54  
10.2.1.  Primary Endpoint Analyses  .................................................................................... 54  
10.2.2.  Secondary Endpoint  Analys es ................................................................................. 56  
10.2.3.  Exploratory Endpoint An alyses ............................................................................... 57  
10.3.  Safety Analyses ...................................................................................................... 58  
10.3.1.  Extent of E xposure ................................................................................................. 58  
10.3.2.  Adverse Events ....................................................................................................... 58  
10.3.3.  Laboratory Analyses ............................................................................................... 59  
10.3.4.  Vital Signs .............................................................................................................. 59  
10.4.  Pharmacokinetic Analyses ...................................................................................... 59  
10.5.  Immunogenicity Analys es....................................................................................... 59  
10.6.  Other Exploratory Analyses .................................................................................... 59  
10.7.  Sample Size Consideration ..................................................................................... 60  
10.8.  Interim Analyses ..................................................................................................... 60  
10.9.  Missing Data Handling and Censoring Rules .......................................................... 60  
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 8 11. STUDY COMMITTEES ........................................................................................ 62  
11.1.  Independent Data M onitoring Co mmittee ............................................................... 62  
12. SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS ........................................................................................... 63  
12.1.  Access to Information for Monitoring ..................................................................... 63  
12.2.  Access to Information for A uditing or Inspections .................................................. 63  
13. QUALITY ASSURANCE AND QUALITY CONTROL ........................................ 64  
13.1.  Regulatory Authority Approval............................................................................... 64  
13.2.  Quality Assu rance .................................................................................................. 64  
13.3.  Study Site Insp ections  ............................................................................................. 64  
13.4.  Drug Account ability ............................................................................................... 64  
14. ETHICS/PROTECTION OF HUMAN PATIENTS ................................................ 66  
14.1.  Ethical Standard ..................................................................................................... 66  
14.2.  Institutional Review Board/Inde pendent Ethics  Committee ..................................... 66  
14.2.1.  Protocol Amendments............................................................................................. 66  
14.3.  Informed Consent ................................................................................................... 67  
14.4.  Patient and Data Confidentiality ............................................................................. 67  
14.5.  Financial Disclosure ............................................................................................... 68  
15. DATA HANDLING AND RECORD KEEPING .................................................... 69  
15.1.  Data Collection and Mana gement Resp onsibilitie s .................................................. 69  
15.1.1.  Data Entry in the Electronic Case Report Form ....................................................... 69  
15.1.2.  Data Collection ....................................................................................................... 69  
15.1.3.  Data Management/Coding ...................................................................................... 69  
15.2.  Study Records Re tention......................................................................................... 70 
15.3.  Protocol Deviations ................................................................................................ 71  
15.4.  Study Report and P ublicati ons ................................................................................ 71  
15.5.  Study and Study Cent er Clos ure ............................................................................. 72  
15.6.  Information Disclosure  and Inventions.................................................................... 72  
16. REFERENCES ....................................................................................................... 74  
17. APPENDICES ........................................................................................................ 76  
APPENDIX 1.  SCHEDULE OF ASSESSMENTS ................................................................. 77  
APPENDIX 2.  PHARMACOKINETIC AND ANTIDRUG ANTIBODY BLOOD 
SAMPLING ........................................................................................................... 81  
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 9 APPENDIX 3.  CLINICAL LABORATORY ASSESSMENTS .............................................. 82  
APPENDIX 4.  CONTRACEPTION GUIDELINES AND DEFINITIONS OF 
‚ÄúWOMEN OF CHILDBEARING POTENTIAL,‚Äù ‚ÄúNO CHILDBEARING 
POTENTIAL‚Äù ........................................................................................................ 83  
 
LIST OF TABLES 
Table 1:  Projected Safety Margins at Proposed Doses in  Humans  ......................................... 20  
Table 2:  Timeframes and Documentation Methods  for Reporting Serious Adverse 
Events to the Sponsor  or Desi gnee .......................................................................... 48 
Table 3:  Treatment Modifications for Symptoms of Infusion-Related Reactions Due to Study Dr ug ......................................................................................................... 51
 
Table 4:  Parameter(s) in Each Model .................................................................................... 55  
Table 5:  Censoring Rules for Analysis of Time-to-even t Endpoint s ...................................... 61  
 
LIST OF FIGURES 
Figure 1:  Simulated BGB-DXP593 Serum and Lung (Assuming 1% Biodistribution) 
Concentration-Time Profiles in Humans ................................................................. 20  
Figure 2:  Study Sche ma ......................................................................................................... 25 
Figure 3:  Shape of the Considered Dose Respons e Patterns for the MCPMod Analysis .......... 55  
 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 11 x Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse 
events (SAEs) 
x PK parameters: maximum observed concentration (C max), area under the concentration-time 
curve (AUC) from time zero to the time of the last quantifiable concentration (AUC t), AUC 
from time zero to Day 29 (AUC 0-29), AUC from time zero to infinity (AUC inf), time to 
maximum observed concentration (t max), terminal half-life (t 1/2), clearance (CL), and volume of 
distribution (V z) as appropriate 
x Immunogenic responses to BGB-DXP593 evaluated through the detection of antidrug antibodies (ADAs) 
Exploratory: 
Study Design 
This is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the safety and 
efficacy of BGB-DXP593 in patients with mild to moderate COVID-19. 
After providing written informed consent, completing all screening assessments, and being confirmed 
as eligible for study participation, patients will be randomized in a 1:1:1:1 ratio to receive placebo, BGB-DXP593 5 mg/kg, BGB-DXP593 15 mg/kg, or BGB-DXP593 30 mg/kg. Patient randomization 
will be stratified by country and disease severity (mild versus moderate COVID-19). The patients will 
receive a single intravenous infusion of placebo or BGB-DXP593 over 30 to 90  minutes. The patients 
will then be followed to Day 113 (¬± 7 days) to assess the efficacy, safety, PK, and immunogenicity. 
Nasopharyngeal swabs will be collected according to the Schedule of Assessments to evaluate the 
change in viral load using RT-qPCR testing of SARS-CoV-2. 
An Independent Data Monitoring Committee (IDMC) will periodically monitor safety and efficacy 
data. The first safety review is planned after at least 12 patients have received study treatment and have 
been followed up for 7 days. 
The study design schema is in Section 3, Figure 2.  
Study Assessments: 
Patients will be monitored for safety, effi cacy, PK, and im munogenicity during the study. 
Assessments of safety will include adverse events, SAEs, clinical laboratory tests, physical 
examinations, vital signs, and electrocardiograms (ECGs). Adverse events will be graded for severity 
per the current version of the National Cancer Institute-Common Terminology Criteria for Adverse 
Events (NCI-CTCAE) Version 5.0. 
PK, ADA and biomarker sampling will be collected at specific intervals from Day 1 to Day 113. 
RT-qPCR analysis will be used to assess the SARS-CoV-2 viral load in different samples at various 
timepoints, including nasopharyngeal swabs, saliva, and blood.  
Version .0 VV-CLIN-073998 1

BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 12 World Health Organization (WHO) 8-poi nt ordinal scale will be used for clinical status assessment. 
Key Eligibility Criteria: 
To participate in this study, patients must have laboratory-confirmed SARS-CoV-2 infection (positive 
reverse transcription-polymerase chain reaction [RT-P CR] test or other testing methods authorized by 
local regulatory authorities) in any samples following local practice ¬î72 hours prior to screening; 
have experienced COVID-19 symptoms for ¬î  7 days prior to treatment assignment (such as fever, 
cough, shortness of breath, sore throat, diarrhea, vomiting, and dysgeusia); and agree to the collection of nasopharyngeal swabs, saliva, and venous blood. Patients should not have oxygen saturation (SpO
2) 
¬î% on room air or ratio of arterial oxygen partial pressure (PaO 2 in millimeters of mercury) to 
fractional inspired oxygen (FiO 2UHVSLUDWRU\UDWH¬ïPLQ or KHDUWUDWH¬ïPLQ3DWLHQWV
should have no history of a positive SARS-CoV-2 serology test; no prior investigational intervention 
for SARS-CoV-2 prophylaxis within 30 days before dosing; and no prior treatment with a 
SARS-CoV-2 specific monoclonal antibody or convalescent COVID-19 plasma; and should not have 
participated in a previous SARS-CoV-2 vaccine study. 
Investigational Product, Dose, and Mode of Administration: 
BGB-DXP593 will be administered intravenously at a dose of 5 mg/kg, 15 mg/kg or 30 mg/kg for 30 
to 90 minutes; placebo will be administered intravenously for 30 to 90 minutes. 
Statistical Methods:  
Analysis Sets 
The Intent-to-Treat (ITT) Analysis Set includes all randomized patients. Patients will be analyzed 
according to the treatment assigned at  randomization. This will be the primary analysis set for efficacy 
analyses. 
The Safety Analysis Set includes all patients who have received the study drug (BGB-DXP593 or 
placebo). Patients will be analyzed according to their actual treatment received. The Safety Analysis Set will be used for all safety analyses. 
The PK Analysis Set includes all patients who have received the study drug (BGB-DXP593) per the 
protocol and for whom any postdose PK data are available. 
The ADA Analysis Set includes all the patients who have received the study drug and in whom both 
baseline ADA and at least 1 postbaseline ADA results are available. Primary Efficacy Analysis The statistical hypotheses to be tested for the primary endpoint are as follows:  H
0: there is a flat dose response curve comparing change from baseline to Day 8 in SARS-CoV-2 viral 
shedding in the placebo and the BGB-DXP593 dose groups 
H1: there is a non-flat dose response curve indicating a benefit of BGB-DXP593 over placebo 
The primary analysis uses methodology for dose finding, employing both multiple comparison 
procedures and modelling techniques (MCPMod). The MCPMod procedure allows for simultaneous 
evaluation of different potential dose response patterns, whilst protecting the overall probability of Type I error (one-VLGHGƒÆRI  
Safety Analyses 
Safety will be assessed by monitoring and recording all adverse events, laboratory values, vital signs, 
and physical examinations. Descriptive statistics will be used to analyze all safety data by actual treatment arm in the Safety Analysis Set. 
Pharmacokinetic Analyses 
Noncompartmental or model-based analysis will be carried out for BGB-DXP593 serum 
concentrations. Parameters, such as C
max, tmax, t1/2, AUC t, AUC inf, AUC 0-29, CL, and V z (as appropriate 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 13 for data collected), may be derived and summarized with descriptive statistics (sample size, mean, 
standard deviation, coefficient of variance, median, minimum, maximum, geometric mean, geometric coefficient of variance). Individual serum concentration-versus-time data will be tabulated and plotted 
by dose level. Additional PK analyses may be conducted as appropriate. 
Immunogenicity Analyses 
The immunogenicity results will be summarized using descriptive statistics by the number and 
percentage of patie nts who develop detectable ADAs. The in cidence of positive and neutralizing ADAs 
will be reported for evaluable patients. The effect of immunogenicity on PK and safety may be 
evaluated if data allow. 
Sample Size Calculation  
Forty-one patients are needed with primary endpoint data per arm to provide at least 82% power to 
detect non-flat dose-response relationship at one- VLGHGVLJQLILFDQFHOHYHOƒÆ 0&30RGDSSURDFK
is used. In order to ensure 41 patients per arm with primary endpoint data, at least 43 patients per arm need to be randomized. 
The calculation has been performed using R software, version 3.6.1.  
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 14 LIST OF ABBREVIATIONS AND TERMS 
Abbreviation Definition 
ACE2 angiotensin-converting enzyme 2 
ADA antidrug antibody 
AE adverse event 
AUC area under the concentration-time curve 
AUC inf AUC from time zero to infinity 
AUC t AUC from time zero to the time of the last quantifiable concentration 
AUC 0-29 AUC from time zero to Day 29 
CI confidence interval 
CL clearance 
Cmax maximum observed concentration 
COVID-19 coronavirus disease 2019 
ECG electrocardiogram 
eCRF electronic case report form 
EDC electronic data capture (system) 
GCP Good Clinical Practice 
IC50 concentration for inhibition of 50% maximal activity 
IC99 concentration for inhibition of 99% maximal activity 
ICF informed consent form 
IDMC Independent Data Monitoring Committee  
IEC Independent Ethics Committee 
IRB Institutional Review Board 
IRT Interactive Response Technology 
mAb monoclonal antibody 
MCPMod multiple comparison procedures and modelling approaches 
MedDRA Medical Dictionary for Regulatory Activities 
NCI-CTCAE National Cancer Institute-Common Terminology Criteria for Adverse Events 
PK pharmacokinetic(s) 
RBD receptor binding domain 
RT-PCR reverse transcription-polymerase chain reaction 
RT-qPCR reverse transcription-quantitative polymerase chain reaction 
SAE serious adverse event 
SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2 
TEAE treatment-emergent adverse event  
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 15 Abbreviation Definition 
tmax time to maximum observed concentration 
t1/2 terminal half-life 
Vz volume of distribution 
 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 16 1. INTRODUCTION AND RATIONALES 
1.1. Introduction 
Coronavirus Disease 2019 (COVID-19) is an acute respiratory infection caused by a new strain 
of coronavirus: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Zhou et al 2020). As of July 2020, over 14 million confirmed cases of COVID-19 worldwide have been 
reported to World Health Organization (WHO). COVID-19 is threatening the global public 
health, and the ongoing spread of COVID-19 has resulted in a worldwide pandemic demanding 
effective interventions against SARS-CoV-2 infections.  
Currently, several treatment strategies are used clinically or are under development, such as 
viral-targeting therapeutics and host-targeting agents (such as anti-interleukin-6 antibodies, 
glucocorticoids) for the treatment of COVID- 19. Unfortunately, there is no vaccine or 
prescribing drug regimen which has demonstrated  significant efficacy in the treatment of 
COVID-19 patients in clinical studies so far ( Jean et al 2020 ). 
Convalescent plasma therapy has been used to treat COVID-19 by providing passive immune 
responses to viral infection. However, the outco mes of passive plasma therapy are unpredictable 
due to the variability of sera from different patients ( Zhou and Zhao 2020 ). Convalescent plasma 
therapy is also associated with other risks, such as transfusion-related acute lung injury, 
transfusion-related overload, or transfusion transmitted infection ( Sullivan and Roback 2020 ). 
Neutralizing monoclonal antibodies (mAbs) gene rated from plasma of convalescent patients 
provide more specific and consistent immune response. The antibodies with high affinity to the 
virus can be selected. Although several SARS -CoV-2-specific neutralizing mAbs are under 
clinical investigation, no clinical studies have been completed to date. Therefore, neutralizing antibodies that effectively block virus entr y into host cells are urgently needed ( Cao et al 2020 ). 
BGB-DXP593 (also named DXP593, BD-368-2, and WBP2281) is a highly potent neutralizing 
immunoglobulin G (IgG)1 monoclonal antibody specifically against SARS-CoV-2. 
1.2. BGB-DXP593 as a SARS-CoV-2 Neutralizing Monoclonal Antibody 
SARS-CoV-2 infects host cells through binding to human angiotensin-converting enzyme 2 
(ACE2) expressed on host cells by the receptor-binding domain (RBD) of its Spike (S) protein 
(Walls et al 2020 ). BGB-DXP593 binds to the S protein RBD of SARS-CoV-2 with high 
specificity and affinity, efficiently blocking the binding of RBD to ACE2, thus preventing virus 
from entering host cells. 
1.2.1.  Nonclinical 
1.2.1.1.  Pharmacology 
BGB-DXP593 binds to the S protein RBD of SARS-CoV-2 with high specificity and affinity, as 
demonstrated by target-binding assays and surface plasmon resonance characterization 
(equilibrium dissociation constant [K D@ Q0%*% -DXP593 efficiently blocks the 
binding of RBD to its receptor ACE2 with a concentration for inhibition of 50% maximal activity (IC
50) of 0.81 nM in a competition enzyme-linked immunosorbent assay (ELISA). 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 17 The crystal structure of BGB-DXP593 antigen-binding fragment (Fab) in complex with RBD 
suggests that BGB-DXP593 would interfere with the interaction between RBD and ACE2. The 
structure shows that  of 
RBD have direct contact with BGB-DXP593. In addition, the structure also suggests that 
BGB-DXP593 would clash with both protomers in the ACE2 dimer.  
In cell-based assays, BGB-DXP593 inhibits SARS-CoV-2 infections in both pseudovirus and 
authentic virus systems with an IC 50 of 8 pM (0.0012 ¬ó g/mL) and 0.1 nM (0.015 ¬óg/mL), 
respectively, and a concentration for inhibition of 99% maximal activity (IC 99) of 0.6 nM 
(0.09 ¬óg/mL) and 1.08 nM (0.162 ¬óg/mL). BGB-DXP593 has wild-type human IgG1 fragment 
crystallizable region (Fc), which exhibit similar bi nding profile as regular IgG1 antibody in terms 
of binding to Fc »ñUHFHSWRUV)F»ñ5V ) and complement 1q (C1q), suggesting competent functions 
of antibody effector. 
The neutralization efficacy of BGB-DXP593 against SARS-CoV-2 was assessed in two different 
models: human ACE2 (hACE2)-transgenic mice model and hamster (Mesocricetus auratus) 
model. The in vivo experiment s exhibited that BGB-DXP593 could provide strong post-exposure 
prophylactic protection against SARS-CoV-2 in both models. 
In hACE2 transgenic mice, 20 mg/kg BGB-DXP593 efficiently prevented SARS-CoV-2 virus 
from infecting lung tissues, achieving undetectable  viral levels in th e prophylactic treatment 
model, where BGB-DXP593 was injected 24 hours befo re the virus infection. Consistent with 
this observation, the body weights of the treated mice remained in stasis while that of the control mice dropped by over 5% at 5 days post infection. Similarly, BGB-DXP593 reduced the virus load by over 1000 fold in the post-exposure proph ylaxis treatment model, where antibody was 
injected 2 hours after the infection. Additionally , the body weight of the treated mice remained 
unchanged over a course of 5 days, comparable to  those in the prophylactic treatment model, 
suggesting that BGB-DXP593 maintained the fitness of the infected mice. 
In the hamster post-exposure prophylaxis trea tment model, BGB-DXP593 injection at a dose 
level of 2, 5, 10, or 20 mg/kg led to dose-depe ndent lung viral reduction at 7 days post infection, 
with the best response observed within the highest tested dose group (ie, 20 mg/kg). All dose 
groups showed improvement in body weight loss compared with the control group. 
BGB-DXP593 (20 mg/kg) also demonstrated a preven tive effect in hamster model when injected 
1 day or 3 days before infection, while the mo re contemporaneous injection (ie, 1 day before 
infection) achieved superior viral load  reduction and body weight maintenance. 
Please refer to the BGB-DXP593 Investigator‚Äôs Brochure  for additional details regarding 
nonclinical studies of BGB-DXP593. 
Version .0 VV-CLIN-073998 1

BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 18 1.2.1.2.  Toxicology 
The toxicity and toxicokinetic profile of  BGB-DXP593 was characterized in a 14-day 
repeat-dose toxicology study followed by a 28- day recovery in cynomolgus monkeys via 
intravenous infusion. A tissue cross reactivity was evaluated in the normal frozen tissues from 
both monkeys and humans. Cytokine release res ponses were evaluated using human peripheral 
blood mononuclear cells (PBMCs). All the data coll ection and analyses have been completed in 
these studies except for the recovery phase data and antidrug antibody (ADA) results in the 14-day repeat-dose study. Based on the available data, the missing information is not considered 
to have an impact on the results and data interpretation.  
In the 14-day repeat-dose study in monkeys at the doses up to 300 mg/kg, no mortality or 
morbidity was noted throughout the study; no trea tment-related findings or changes were noted, 
which included clinical observations, body weights, body temperature, ophthalmology, 
hematology, coagulation, serum chemistry, urinalysis, cytokines, gross lesions, organ weights 
and histopathology; no treatment-rel ated changes in the cardiovascular, respiratory, or central 
nervous systems functions were noted. The sy stemic exposure evaluated by area under the 
concentration-time curve (AUC) from time zero to the 169.5 hours (AUC
0-169.5h ) and maximum 
observed concentration (C max) appeared to increase dose proportionally without apparent sex 
differences. No marked drug accumulation or changes were noted after weekly repeated doses. 
The NOAEL (No Observed Adverse Effect Level) is considered as 300 mg/kg in this study 
based on available data, which is  approximately 60-fold of the proposed first-in-patient dose 
(5 mg/kg) and 10-fold of the proposed highest human dose (30 mg/kg) based on body weight. 
No specific binding of BGB-DXP593 was detected in  either normal monkey or human tissues in 
the tissue cross reactivity study by immunohist ochemical method. No apparent BGB-DXP593 
specific cytokine releases were detected in human PBMCs. Please refer to the BGB-DXP593 Investigator‚Äôs Brochure  for more detailed information on the 
toxicology of BGB-DXP593. 
1.2.2.  Clinical Experience 
A first-in-human study of BGB-DXP593 in healthy subjects (Study BGB-DXP593-101) is 
ongoing. No serious adverse event has been reported to date. 
1.3. Study Rationale 
COVID-19 is an acute respiratory syndrome caused by SARS-CoV-2 infection. BGB-DXP593 is a neutralizing mAb against the SARS-CoV-2 sele cted from convalescent COVID-19 patients. By 
binding to the RBD on the S protein of the virus, BGB-DXP593 can prevent the virus from 
entering the cells. Its pre- and post-exposure pr ophylaxis effects in hACE mice have been 
demonstrated ( Cao et al 2020 ). 
A few studies suggested that high viral load is associated with increased mortality ( Fajnzylber et 
al 2020; Pujadas et al 2020; Wolfel et al 2020). Amongst the participants hospitalized with 
COVID-19, higher prevalence of detectable SARS-C oV-2 plasma viral load was associated with 
worse respiratory disease severity, lower absolu te lymphocyte counts, and increased markers of 
inflammation,
 including C-reactive protein and interleukin-6 ( Fajnzylber et al 2020 ). This study 
will explore if BGB-DXP593 can effectively reduce viral load in collected samples.  
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 19 Patients who have experienced COVID-19 symptoms less than 7 days will be enrolled. By 
7 days after onset of symptoms, anti-SARS-CoV-2 immunoglobulin M (IgM) or IgG can be 
detected in around 50% of patients ( Wolfel et al 2020 ). Presence of anti-SARS-CoV-2 IgG in 
patients‚Äô blood is associated with reduced viral lo ad. High viral loads were rare in individuals 
who had seroconverted ( Bryan et al 2020 ).  
This study will assess efficacy of BGB-DXP593 in lowering viral load at different dose levels. 
To date, there is no drug approved or recommended for mild to moderate COVID-19 ( NIH 
COVID-19 treatment guidelines, 2020 ). Hence, using placebo as the control is appropriate.  
To assess viral load at different time points,  nasopharyngeal swabs, saliva and blood samples 
will be collected. Nasopharyngeal swabs are th e clinically recommended sampling method for 
virologic tests. In addition, the viral load change in saliva samples will be assessed. The viral 
load in nasopharyngeal samples will be used for pr imary efficacy analysis. Collection of saliva is 
non-invasive. Studies suggested that viral lo ads in saliva are comparable to those in 
nasopharyngeal swabs during the first week of symptoms and decrease over time. Saliva can be 
positive up to 20 days post-symptom onset with viral loads correlating with symptom severity 
and degree of tissue damage. The viral load in saliva has good associati on with nasopharyngeal 
swabs ( Khurshid et al 2020 ). A majority of patients do not ha ve viremia. However, detection of 
viral RNA in blood is associated with poor outcomes. 
1.3.1.  Rationale for Selection of BGB-DXP593 Doses  
A single dose of BGB-DXP593 of 5 mg/kg, 15 mg/kg and 30 mg/kg, as the dose levels being 
tested, are proposed based on an overall assessment of in vitro activity of BGB-DXP593 and 
toxicology data as describe below. 
Based on the toxicology evaluation in cynomolgus  monkeys, the NOAEL was determined to be 
300 mg/kg. Applying a safety factor of 10, the MRSD (maximum recommended starting dose) is 
estimated as 30 mg/kg (body weight-based) which is  the highest dose being tested in this study. 
In addition, based on the AUC from time zero to infinity (AUC inf) and C max after the second dose 
at 300 mg/kg NOAEL in the toxicity study in monkeys, the projected safety margins at the proposed highest dose of 30 mg/kg are 5.0 and 11.1, respectively, which reflects favorably on the safety profile of BGB-DXP593 ( Table 1 ). 
The two lower doses of 5 mg/kg and 15 mg/kg are based on the results of the in vitro virus neutralization assays. In the in vitro virus ne utralization assays, BGB-DXP593 potently inhibited 
SARS-CoV-2 infections in both pseudovirus and authentic virus systems with an IC
99 of 
0.09 ¬óg/mL and 0.162 ¬óg/mL, respectively. Predicted serum a nd lung concentrations at various 
dose levels were compared to the IC 99 of 0.162 ¬ó g/mL from the authentic virus neutralization 
assay (higher value from the two assays). The bi odistribution of monoclonal antibodies in lungs 
was taken into consideration. It has been reporte d in literature that lung biodistribution ranges 
from 0.5% to 15% ( Hart et al 2001; Shah and Betts 2013; Hershberger et al 2019; Eigenmann et 
al 2017), therefore, a conservative value of 1% lung biodistribution was chosen for the simulations.  
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
CONFIDENTIAL Page 20 Predicted human serum concentration-time pr ofiles showed that BGB-DXP593 doses at and 
above 5 mg/kg would maintain l ung concentrations above the IC 99 of 0.162 ¬ó g/mL over 29 days
(Figure 1 ). However, given that the impact of SARS-CoV-2 on lung biodistribution of 
monoclonal antibodies is not known, the two higher dose levels of 15 mg/kg and 30 mg/kg will 
also be tested. 
Please refer to the BGB-DXP593 Investigator‚Äôs Brochure  for more detailed information. 
Figure 1: Simulated BGB-DXP593 Serum and Lung (Assuming 1% Biodistribution) 
Concentration-Time Profiles in Humans 
 
Abbreviation: IC 99, concentration of BGB-DXP593 required to achieve 99% inhibition of host cell infection in vitro 
in an authentic virus neutralization assay. 
Solid lines: projected serum concentrations; dashed lines: projected lung concentrations assuming 1% 
biodistribution. 
Table 1: Projected Safety Margins at Proposed Doses in Humans 
Safety margin BGB-DXP593 Dose (mg/kg) 
5 15 30 
AUC based 30.3 10.1 5.0 
Cmax based 66.4 22.1 11.1 
Abbreviations: AUC, area under the concentration-time curve; C max, maximum observed concentration 
1.3.2.  Rationale for Pharmacokinetic Sampling 
The sampling schedule that follows the single dose of BGB-DXP593 is designed to capture data 
at a sufficient number of timepoints to provide a detailed profile of the concentration-time curve, 
including C max, AUC from time zero to the time of the last quantifiable concentration (AUC t), 
AUC from time zero to Day 29 (AUC 0-29), AUC inf, time to maximum observed concentration 
(tmax), terminal half-life (t 1/2), clearance (CL), and volume of distribution (V z). 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 21 Rich PK sampling will be performed in the first-in-human study in healthy subjects (Study 
BGB-DXP593-101). PK sampling in this study is limited to essential site visits to reduce patient 
burden. 
1.3.3.  Rationale for Biomarker Strategy 
Biomarker analyses will be performed to evaluate  study treatment effects induced in patients as 
well as to explore potential predictive biomarkers of response to BGB-DXP593. 
Seroconversion for patients with COVID-19 usually happens within the first week after symptom 
onset ( Wolfel et al 2020 ). It has been shown that seroconversion occurred after 7 days in 50% of 
patients and almost all COVID- 19 patients had neutralizing antibodies within 1 month after 
symptom onset, thus the existing anti-SARS-CoV-2 antibodies in patients may have an impact 
on the efficacy of BGB-DXP593, which is also an neutralizing antibody for SARS-CoV-2. Therefore, the baseline SARS-CoV-2 serology an tibody levels may be rela ted to the treatment 
effects of BGB-DXP593. Recent studies have suggested that the certain mutations on SARS-CoV-2 virus may impact the infectivity and se verity of the virus, especially the mutations 
on the receptor binding domain of SARS-CoV-2, which may also impact the neutralizing 
activities of SARS-CoV-2 neutralizing antibodies ( Baum et al 2020 ; Korber et al 2020 ; Li et al 
2020). Thus, certain mutations on SARS-CoV-2 genome may also be related to the treatment effects of BGB-DXP593.  
In addition, patients with COVID-19 have s hown a strong upregulation of cytokine and 
interferon production, it is believed that dys regulated host immune response and production of 
inflammatory cytokines, known as the ‚Äúcytokine storm‚Äù, correlates with disease severity and 
poor prognosis of SARS-CoV-2 infection ( Tay et al 2020 ). Therefore, serum cytokine levels 
could be a marker for evaluating disease severity and the treatment effects of anti-SARS-CoV-2 
neutralizing antibodies. 
Considering the immune response induced by SARS-CoV-2 infection varies a lot among 
different patients, all patients may not be equally likely to benefit from treatment with 
anti-SARS-CoV-2 neutralizing antibodies. Predicti ve biomarker samples collected before dosing 
will be assessed in an effort to identify those patients with certain gene signatures who are most likely to respond to BGB-DXP593. Thus, gene signatures at baseline and after treatment in peripheral blood may serve as predictive biom arkers and may also help to explore the 
mechanism of response. 
1.4. Benefit-Risk Assessment 
On March 11, 2020, the Novel Coronavirus Disease, COVID-19, was declared a pandemic by the WHO. As of July 9, 2020, more than 12 million cases of COVID-19 have been reported 
globally, including more than 550,000 deaths. However, only remdesivir is approved for the treatment of severe COVID-19, and thus  the unmet medical needs remain high. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 22 Several studies showed that high viral load is associated with increased mortality. 
Seroconversion (detection of anti-SARS-CoV-2 IgM or IgG in blood) occurred in around 50% of 
patients 7 days after disease onset. Presence of anti-SARS-CoV-2 IgG is associated with viral load reduction ( Bryan et al 2020; Fajnzylber et al 2020;  Pujadas et al 2020; Wolfel et al 2020 ). 
With early administration of antiviral neutra lizing antibodies, patients may benefit from early 
and rapid reduction of viral load and potential improved clinical outcomes. 
BGB-DXP593 is a potent neutralizing antibody to SARS -CoV-2. It is human IgG type 1 selected 
from blood of convalescent patients. In prec linical studies, its pre- and post-exposure 
prophylactic effects to COVID-19 have been demons trated. In a toxicological study in monkeys, 
no adverse events (AEs) were observed with repeated doses of BGB-DXP593 30-300 mg/kg.  
As an exogeneous protein, use of BGB-DXP593 mi ght be related with hype rsensitivity reactions, 
though the immunogenicity is considered lo w due to its human origin. Potential 
antibody-dependent enhancement ( ADE) has been observed in some viral infections, such as 
Dengue fever. Possibility of ADE with passiv e immunity cannot be excluded in COVID-19. 
However, clinical experiences with RSV, influenza and dengue provide strong evidence that the 
circumstances that are proposed to lead to  ADE of disease‚Äîincluding low affinity or 
cross-reactive antibodies with limited or no neut ralizing activity or suboptimal titres‚Äîare very 
rarely implicated as the cause of severe viral infection in the human host ( Arvin et al 2020 ). 
BGB-DXP593 is a highly potent neutralizing antibody, and thus is unlikely to cause ADE. In 
addition, a large number of COVID-19 patients ha ve received convalescent plasma therapy, 
where no hints of ADE have been identified ( Joyner et al 2020 ).  
There are no FDA-approved treatments or accep ted standardized medi cal treatment options 
indicated for mild to moderate COVID-19. Patients may benefit from the treatment of 
BGB-DXP593 based on its mechanism of action and the proven efficacy in COVID-19 animal models. BGB-DXP593 has a favorable preclinical safe ty profile. Patients enro lled in this clinical 
study will be closely monitored by means of reporting AEs, recording vital signs, and conducting clinical laboratory safety tests of blood and urine. The favorable preclinical safety profile, potential wide range application in the COVI D-19 population and high unmet medical need 
provides substantive evidence that BGB-DXP593 has a favorable risk-benefit profile.  
1.5. Study Conduct 
This study will be conducted in  compliance with the protocol approved by the Institutional 
Review Board (IRB) or Independent Ethics Committee (IEC) and in accordance with Good 
Clinical Practice (GCP) standards. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 23 2. STUDY OBJECTIVES AND ENDPOINTS 
2.1. Study Objectives 
2.1.1.  Primary Objective 
x To evaluate the efficacy of BGB-DXP593 administered intravenously as a single dose in 
patients with mild to moderate COVID-19 
2.1.2.  Secondary Objectives 
x To evaluate the safety of BGB-DXP593 administered intravenously as a single dose in patients with mild to moderate COVID-19 
x To characterize the pharmacokinetic (PK) profile of BGB-DXP593 administered intravenously as a single dose in patients with mild to moderate COVID-19 
x To evaluate the potential immunogenicity of BGB-DXP593 administered intravenously 
as a single dose in patients with mild to moderate COVID-19 
2.1.3.  Exploratory Objective 
x 
2.2. Study Endpoints 
2.2.1.  Primary Endpoint 
x Change from baseline to Day 8 in Severe Acute Respiratory Syndrome Coronavirus 2 
(SARS-CoV-2) viral shedding as measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal swab samples 
2.2.2.  Secondary Endpoints 
x Time-weighted average change in SARS-CoV -2 viral shedding as measured by RT-qPCR 
in nasopharyngeal swab samples from baseline to Day 15 
x Change in SARS-CoV-2 viral shedding as measured by RT-qPCR in nasopharyngeal swab samples from baseline to Day 15 
x Time to negative RT-qPCR in all tested samples with no subsequent positive RT-qPCR in any tested samples 
x Proportion of patients requiring hospitalization due to worsened COVID-19 
x Time to resolution of all COVID-19-related symptoms 
x All-cause mortality rate at Day 29 
x Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) 
Version .0 VV-CLIN-073998 1

BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 24 x PK parameters: maximum observed concentration (C max), area under the 
concentration-time curve (AUC) from time zero to the time of the last quantifiable 
concentration (AUC t), AUC from time zero to Day 29 (AUC 0-29), AUC from time zero to 
infinity (AUC inf), time to maximum observed concentration (t max), terminal half-life (t 1/2), 
clearance (CL), and volume of distribution (V z) as appropriate 
x Immunogenic responses to BGB-DXP593 evaluated through the detection of antidrug antibodies (ADAs) 
2.2.3.  Exploratory Endpoints 
Version .0 VV-CLIN-073998 1

BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 25 3. STUDY DESIGN 
3.1. Summary of Study Design 
This is a Phase 2, randomized, double-blind, pl acebo-controlled study to evaluate the efficacy 
and safety of BGB-DXP593 in patients with mild to moderate COVID-19. 
The study will be conducted across approxima tely 20 to 30 site s internationally. 
After providing written informed consent, comp leting all screening a ssessments, and being 
confirmed as eligible for study pa rticipation, patients will be randomized in a 1:1:1:1 ratio to 
receive placebo, BGB-DXP593 5 mg/kg, BGB-DXP593 15 mg/kg, or BGB-DXP593 30 mg/kg. 
Patient randomization will be stratified by country  and disease severity (mild versus moderate 
COVID-19). The patients will receive a single intravenous infusion of placebo or BGB-DXP593 
over 30 to 90 minutes. The patients will then be followed to Day 113 (¬± 7 days) to assess the 
efficacy, safety, PK, and immunogenicity. Nasopharyngeal swabs will be collected according to the Schedule of Assessments ( Appendix 1) for RT-qPCR testing of SARS-CoV-2 to assess the 
change in viral load after study treatment. A pproximately 172 patients will be randomized. 
An Independent Data Monitoring Committee (IDMC) will periodically monitor safety and efficacy data. The first safety review is planned after at least 12 patients have been treated and 
followed up for 7 days. 
The study schema is provided in Figure 2 . 
Figure 2: Study Schema 
 
NRte: Patients will be randomized based on stratification factors of country and disease severity (mild versus 
moderate COVID-19).  
Patients will be monitored for safety, effi cacy, PK, and immunogenicity during the study. 
Assessments of safety will include AEs, SAEs, clinical laboratory tests, physical examinations, 
vital signs, and electrocardiograms (ECGs). AEs will be graded for severity according to the 
current version of the National Cancer Ins titute-Common Terminology Criteria for Adverse 
Events (NCI-CTCAE) Version 5.0. Refer to Section 9 for additional and specific information 
regarding AE monitoring and reporting. 
RT-qPCR analysis will be used to assess the SARS-CoV-2 viral load in different samples at 
various timepoints, including nasopharyngeal swabs, saliva, and blood. The viral load in 
nasopharyngeal swabs will be used for primary efficacy analysis.  
WHO 8-point ordinal scale will be used for clinical status assessment. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 26 PK and ADA sampling will be conducted at timepoints specified in Appendix 2 . 
Biomarker analysis will include, but are not limited to, SARS-CoV-2 mutations, serology, 
cytokines, and gene expression signatures. 
Study procedures and assessments ar e further detailed in Section 7 and Section 8, respectively, 
and the Schedule of Assessments can be found in Appendix 1.  
 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 27 4. STUDY POPULATION 
The specific eligibility criteria for selection of patients are provided in Section 4.1 and 
Section 4.2. The sponsor will not grant any eligibility waivers. 
4.1. Inclusion Criteria 
Each patient must meet all of the following inclusion criteria to be considered eligible for 
participation in this study: 
1. Participant must be at least 18 years of age at the time of signing the informed consent.  
2. Laboratory-confirmed SA RS-CoV-2 infection (positive  reverse transcription-polymerase 
chain reaction [RT-PCR] test or other tes ting methods authorized by local regulatory 
authorities) in any samples following local practice ¬î 72 hours prior to screening 
3. Have experienced COVID-19 symptoms for ¬î 7 days prior to treatment assignment, such 
as fever, cough, shortness of breath, sore  throat, diarrhea, vomiting, and dysgeusia 
4. Agree to the collection of nasopharynge al swabs, saliva, and venous blood 
5. Female patients of childbearing potential must be willing to use a highly effective method 
of birth control (see Appendix 4 ) from the time of study enrollment until 4 months after 
the study dosing 
6. Male patients with female partners of childbearing potential must be willing to use a highly effective method of birth control (see Appendix 4) from the time of study enrollment until 4 months after the study dosing 
7. Able to provide written informed consent a nd can understand and agree to comply with 
the requirements of the study and the schedule of assessments 
4.2. Exclusion Criteria 
Patients who meet any of the following cr iteria will be excluded from this study: 
Medical Histories or Conditions 
1. Patient with severe COVID- 19 having oxygen saturation (SpO 2¬îRQURRPDLURU
ratio of arterial oxygen partial pressure (PaO 2 in millimeters of mercury) to fractional 
inspired oxygen (FiO 2) < UHVSLUDWRU\UDWH¬ïPLQ or heart UDWH¬ï  125/min 
Note: For high altitude areas, PaO 2/FiO 2 ratio should be adjusted using formula: 
PaO 2/[FiO 2√ó(barometric pressure/760)]  
2. Patient requires mechanical ventilation or anticipated impending need for mechanical ventilation 
3. Known allergies to any of the components used in the formulation of the interventions 
4. Hemodynamic instability requiring use of pre ssors within 24 hours prior to treatment 
assignment 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 28 5. Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides 
COVID-19) that in the opinion of the inves tigator could constitute a risk when taking 
intervention 
6. Any comorbidity requiring surgery within 7 days prior to screening, or that is considered 
life-threatening within 29 days prior to screening  
7. Any serious concomitant systemic disease, c ondition, or disorder that, in the opinion of 
the investigator, should preclude participation in this study 
8. History of a positive SARS-CoV-2 serology test (anti-SARS-CoV-2 IgA, IgM, or IgG) 
9. History of a positive SARS-CoV-2 test (RT-P CR or other testing authorized by local 
regulatory authorities) prior to the one serving as eligibility for this study 
10. Pregnant or breast feeding 
11. Any concurrent immune-compromising conditions, including a) a known history of 
immunodeficiency disorders; b) malignant or nonmalignant disorders requiring use of 
immunosuppressive therapies 
12. Any history of a severe allergic reaction prior to enrollment that has a reasonable risk of 
recurrence during the study 
Prior/Concomitant Therapy 
13. Have received an investiga tional intervention for SARS-CoV-2 prophylaxis within 
30 days before dosing 
14. Have received treatment with a SARS-C oV-2 specific monoclonal antibody  
15. History of convalescent COVID-19 plasma treatment 
16. Have received remdesivir 
17. Have received any investiga tional treatment for COVID-19, including but not limited to 
antiviral agents, corticosteroids, interleukin-1 inhibitors, interleukin-6 inhibitors and intravenous immunoglobulin within 30 days before dosing 
Prior/Concurrent Clinical Study Experience 
18. Participation in a previous SARS-CoV-2 vaccine study 
19. Participation, within the la st 30 days, in a clinical st udy involving an investigational 
intervention. If the previous investigational intervention has a long half-life, 5 half-lives 
or 30 days, whichever is longer, should have passed. 
20. Concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 29 Diagnostic Assessments 
21. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x upper limit of 
normal (ULN), and/or bilirubin > 2 x ULN 
22. Liver insufficiency classified as Child-Pugh Grade C  
23. Renal insufficiency: estimated glomerular filtration rate (eGFR) < 30 mL/min using Cockcroft and Gault formula 
24. Patients who have been hosp italized due to COVID-19 
For COVID-19 patients that have  been hospitalized regardless of disease severity due to 
local or country regulations, eligibility should be  confirmed with the sponsor or designee.  
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 30 5. STUDY TREATMENT 
5.1. Formulation, Packaging, and Handling 
5.1.1.  BGB-DXP593 
BGB-DXP593 is a neutralizing mAb formulated for intravenous injection in a single-use vial 
(United States Pharmacopeia [USP]  type I), containing a total of 300 mg of antibody in 10 mL of 
buffered isotonic solution. BGB-DXP593 has been aseptically filled in single-use vials with a 
rubber stopper capped by an aluminum flip-off seal. One or multiple single-use vials are packaged into each carton box. The contents of th e label from vials and carton boxes will be in 
accordance with all applicable local regulatory requirements. 
The study drug will be dispatched to the study center only after receipt of the required documents 
in accordance with applicable regulatory requirements and the sponsor‚Äôs procedures. The 
unblinded pharmacist is responsible for ma intaining the drug supply inventory and 
acknowledging receipt of all study drug shipments. The study drug must be stored in a secure 
area, with access limited to the authorized st udy center personnel and kept under physical 
FRQGLWLRQVWKDWDUHFRQVLVWHQWZLWKVWXG\GUXJ·Ä©VSHFLILFUHTXLUH PHQWV%*%·Ä©';3PXVWEH
stored at temperatures between 2¬∞C and 8¬∞C and protected from light. 
Refer to the Pharmacy Manual for details rega rding intravenous administration, accountability, 
and disposal. Please also refer to the BGB-DXP593 Investigator‚Äôs Brochure for other details 
regarding BGB-DXP593. 
5.1.2.  Placebo 
Placebo is a sterile concentrate solution for dilutio n for infusion. It shares the same formulation 
as BGB-DXP593 without the active pharmaceutical  ingredient (BGB-DXP593 antibody). Each 
placebo vial is packaged into a single-carton box. Th e contents of the label for placebo vials will 
be in accordance with all applicable local regulatory requirements. 
The study drug must be kept at the temperature condition as specified on the label. Refer to the Pharmacy Manual for details regard ing intravenous administration, accountability, 
and disposal. 
5.2. Dosage, Administration, and Compliance 
BGB-DXP593 or placebo are administered intravenously with a single dose. On the day of 
dosing, study drug (BGB-DXP593 or placebo) should be reconstituted with 0.9% sodium 
chloride and will be administered by intr avenous infusion for 30 to 90 minutes. Specific 
instructions for BGB-DXP593 preparation and administration are provided in the Pharmacy 
Manual. The dose of BGB-DXP593 for each patient will be based on the patient‚Äôs actual body weight on the day of drug administration. 
As a routine precaution, patients must be monitored for at least 2 hours after the infusion of study 
drug in an area with resuscitation equipment and emergency agents. The study drug must not be administered concurrently  with any other drug. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 31 Accurate records of the study drug received, dispensed, returned, and disposed of should be 
maintained in the site‚Äôs Drug Inventory Log by an unblinded pharmacist. Refer to the Pharmacy Manual for details of study drug management, drug preparation, storage, and administration. 
Guidelines for infusion-related reactions are provided in detail in Section 9.7. 
5.3. Incorrect Administration 
Any incorrect administration of the study drug should be noted in the patient‚Äôs chart and on the 
appropriate electronic case report form (eCRF) without the study drug kit number. AEs associated with an incorrect administration of the study drug will be recorded on the AE eCRF. 
Any SAEs associated with an incorrect administration must be reported within 24 hours of 
awareness via the SAE reporting process as described in Section 9.6.2. Supportive care measures 
should be administered as appropriate. 
5.4. Dose Interruption or Modification 
There will be no dose reduction of study drug in this study. A dose interruption is an interruption 
of an infusion. 
Each patient will receive a single dose of the study drug via intravenous infusion. The infusion 
may be temporarily interrupted due to infusion -related reactions or other medical events. 
If the AE is resolved or recovered to Grade 1 (whichever is more severe), the infusion should be resumed within 2 hours of the infusion interruption. If the patient is unable to resume the study 
drug within 2 hours of the infusion interruption, then the patient should be discontinued from the 
study treatment. 
The treatment modification for infusion-re lated reactions is provided in Section 9.7.1 . 
5.5. Blinding 
In this study, patients will be randomized to receive BGB-DXP593 or matched placebo in a 
double-blind fashion. The single dose of study drug will be prepared by an unblinded pharmacist. 
At the study sites, only the unblinded pharmacis t for study drug preparation will know the 
treatment allocation of pa tients; other members who are direc tly involved in the clinical conduct 
of the study, including the staff for study drug administration, will not know. Both the intravenous infusion of BGB-DXP593 and placebo will be colorless. All the follow-up 
evaluations will be performed by blinded study site st aff. It is imperative to maintain the blind to 
patient treatment assignment such that neither th e investigator, nor the patient, nor medical or 
ancillary medical staff (except for the unblinded pharmacist who is responsible for the preparation of the study drug and has access to dispensation records), nor the blinded sponsor staff or its designees will know which study drug is being administered. Due to the ongoing need 
to assess safety, a limited number of sponsor st aff will not be blinded to patient treatment 
assignment (see Section 11.1). 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 32 Every effort should be made to avoid unblinding the patient‚Äôs treatment assignment unless 
necessary. Unblinding may be indicated and permissible only in specific situations as described 
below and if necessary, for the patient‚Äôs welfare. Unblinding would occur through Interactive 
Response Technology (IRT) as per the instructions in  the IRT site user manual. If unblinding has 
occurred, the sponsor must be notified immediately using the Unblinding Event Form. To ensure the continued blinding of study personnel, this form will not include the treatment assignment.  
Patients will remain on study for study follow-up. 
The study will be unblinded after pr imary analysis database lock. 
5.5.1.  Emergency Unblinding 
In case of an emergency, such as when a patient has an AE suspected to be related to the 
investigational drug product and for which management of the AE with one or more drug 
products with substantial toxic ity or invasive procedures is being considered, unblinding can 
occur. The investigator has the sole responsibility  for determining if unblinding of a patient‚Äôs 
treatment assignment is warranted. Patient safety must always be the first consideration in making such a determination. If the investigator decides that unblinding is warranted, the 
investigator should make every effort to inform the medical monitor of their intent before 
unblinding a patient‚Äôs treatment a ssignment unless this could dela y emergency treatment of the 
patient. If a patient‚Äôs treatment assignment is unblinded, the sponsor must be notified 
immediately. 
The investigator performs the emergency unblinding for AEs through an IRT System. 
5.5.2.  Inadvertent Unblinding 
Every effort will be made to blind both the patient and the investigator to the identity of the 
treatment assignment (ie, BGB-DXP593 or placebo), but the inadvertent unblinding of a patient 
may occur. If an investigator, site personnel pe rforming assessments, or patient is unblinded, the 
unblinding will not be sufficient cause (in and of it self) for that patient to be discontinued from 
study or excluded from any analyses. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 33 6. PRIOR AND CONCOMITANT THERAPY 
6.1. Permitted Concomitant Medications/Procedures 
Unless noted otherwise, most concomitant medications and therapies deemed necessary and in 
keeping with local standards of medical care at th e discretion of the investigator for a patient‚Äôs 
welfare are allowed. Standard of care therapy for mild to moderate COVID-19 is allowed 
according to local treatment guidelines.  
All concomitant medications, including all prescription and over-the-counter drugs, supplements, 
and intravenous medications and fl uids, taken by or administered to  the patient within 30 days 
before the study drug administration and during the study will be recorded in the eCRF including 
indication and dates of administration. 
6.2. Prohibited Concomitant Medications/Procedures 
Any approved or investigationa l drugs with established or potential activity against 
SARS-CoV-2 within 30 days of study drug administration are prohibited, including but not 
limited to, remdesivir, other antiviral agents, corticosteroids, interleukin-1 inhibitors, interleukin-6 inhibitors, and immunoglobulin. If cl inically indicated, patients with worsened 
COVID-19 may be treated with standard of care therapy according to local treatment guidelines. 
For example, dexamethasone is allowed in hospitalized patients requiring oxygen support. 
6.3. Potential Interactions Between the Study Drug and Concomitant 
Medications 
The potential for drug-drug interaction be tween BGB-DXP593 and small-molecule drug 
products is very low, given that BGB-DXP593 is a monoclonal antibody. Because 
BGB-DXP593 is expected to be degraded into amino acids and recycled into other proteins, it is 
unlikely to have an effect on drug metabolizing enzymes or transporters. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 34 7. STUDY PERIODS, VISITS, OR PROCEDURES 
Study periods, visits and procedures are summari zed in the following subsections. The timing of 
all study procedures is provided in the Schedule of Assessments ( Appendix 1 ). 
7.1. Screening Period 
Screening evaluations will be performed within 3 days before the study drug administration. A 
patient who agrees to participate in this study will sign the informed consent form (ICF) before 
undergoing any study-specific procedures. Refer to Section 8.1 for instructions regarding 
screening assessments. Rescreening is not allowed. If the site is able to complete all the 
screening procedures, randomization, and study tr eatment in 1 day, the screening assessments 
can be combined with the Day 1 assessments. 
7.1.1.  Informed Consent and Screening Log 
Voluntary, written informed consent for partic ipation in the study must be obtained before 
performing any study-specific procedures. ICFs for enrolled patients and for patients who are 
screened but not enrolled will be maintained at the study site.  
The investigator will maintain a screening log to record details of all patients screened and to 
confirm eligibility or record reasons for screening failure, as applicable. 
7.1.2.  Patient Numbering 
After obtaining informed consent, study site personnel will access the IRT system to assign a 
unique patient number to a potentia l study participant. Once a pa tient number has been assigned 
to a patient, it cannot be rea ssigned to any other patient. 
7.2. Enrollment 
7.2.1.  Confirmation of Eligibility 
All screening results and relevant medical history must be available before eligibility can be 
determined. The investigator mu st confirm that all eligibility criteria are met. All inclusion 
criteria must be met and none of the exclusion cr iteria may apply. No eligibility waivers will be 
granted. 
7.2.2.  Enrollment/Randomization 
Site personnel will randomize th e patients to treatment arms (placebo, BGB-DXP593 5 mg/kg, 
BGB-DXP593 15 mg/kg, or BGB-DXP593 30 mg/kg) based on stratification factors of country 
and disease severity (mild versus moderate COVID-19), then the unblinded pharmacist will 
access the IRT system and dispense the study drug. 
7.3. Treatment 
Patients randomized will be treated with the study drug on Day 1 as described in Section 5.2. A 
single dose of the study drug will be administered intravenously to the patient. Vital signs of the 
patients will be monitored approxi mately every 15 minutes during the infusion and then hourly 
till 2 hours after the infusion. See Appendix 1 for detailed procedures on Day 1. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 35 Refer to Section 7.5 for additional considerations regarding treatment continuation and 
withdrawal. 
7.4. Follow-up Period 
The follow-up period starts from the next day following the infusion of the study drug through 
Day 113 (¬± 7 days). Safety, efficacy, PK, immuno genicity, and biomarker assessments will be 
performed during the follow-up period as described in Appendix 1  and Appendix 2.  
7.4.1.  End-of-Study Visit 
Patients who permanently discontinue from the study will be asked to return to the study center for the End-of-Study Visit, which is required to be conducted within 7 days after the premature 
study discontinuation. If the patient refuses to return for the End-of-Study Visit or are unable to 
do so, every effort should be made to contact th e patient by telephone to determine their health 
status. 
7.4.2.  Safety Follow-up Visit After Premature Study Discontinuation 
If patients discontinue the study within 30 days after study treatment, a Safety Follow-up Visit 
will be conducted at Day 31 (¬± 3 days) (30 days [¬± 3 days] after study treatment). If the 
premature discontinuation from study occurs within 7 days prior to Day 31 (¬± 3 days), the Safety 
Follow-up Visit can be combined with the End-of -Study Visit or Day 29 visit, as appropriate. 
7.4.3.  Lost to Follow-up 
If attempts to contact the patie nt by telephone are unsuccessful,  additional attempts should be 
made to obtain protocol-required follow-up information. Attempts of contact should be 
documented in the patient‚Äôs source documents. If  a patient cannot be contacted despite all 
attempts, the patient will be considered lost to follow-up. 
7.5. Discontinuation From Study Treatment or From the Study 
7.5.1.  Patient Discontinuation From Study Treatment 
Eligible patients will receive  a complete dose of study drug. Patients have the right to 
discontinue study treatment infusion for any reason. In addition, the investigator has the right to 
discontinue a patient from study treatment. Patients who discontinue  study treatment will remain 
on the study and continue to be followed for protocol-specified follow-up procedures 
(Appendix 1), if possible; this will include, but is not limited to, the safety assessments. 
The primary reason for discontinuation from study treatment should be documented on the 
appropriate eCRF. Patie nts may discontinue study treatment for reasons including but not limited 
to the following: 
x The investigator or sponsor determines it is in the best interest of the patient 
x Significant or persistent adverse event(s) 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 36 7.5.2.  Patient Discontinuation From the Study (End of Study for an Individual Patient) 
Patients may discontinue from the study for reas ons that include, but are not limited to, the 
following: 
x Patient withdrawal of consent 
x Study termination by sponsor 
x Lost to follow-up 
x Completion of all study assessments 
7.6. End of Study 
The end of study is defined as the timepoint wh en the final data for a clinical study were 
collected, which is after the last patient has made the final visit to  the study center. Alternatively, 
the end of study is when the sponsor decides to terminate the study. 
The sponsor has the right to terminate this st udy at any time. Reasons for terminating the study 
early include, but are not limited to, the following:  
x The incidence or severity of AEs in this or other studies indicates a potential health 
hazard to patients 
x Overall patient enrollment is unsatisfactory 
The sponsor will notify each investigator if a deci sion is made to terminate the study. Should this 
be necessary, prematurely discontinued patients must be seen for an End-of-Study Visit as 
described in Section 7.4.1 . 
The investigators may be informed of additiona l procedures to be followed to ensure that 
adequate consideration is given to  the protection of the patient‚Äôs interests. The investigator will 
be responsible for informing IRBs/IECs of the early termination of the study. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 37 8. STUDY ASSESSMENTS 
A table of scheduled study assessments is provided in Appendix 1 . Patients will be closely 
monitored for safety and tolerability throughout the study. All assessments will be performed and 
documented in the medical record for each patient. 
The investigator and/or site personnel s hould use personal preventive equipment (PPE) 
appropriately when performing study assessments and procedures. PPE may be provided by the 
sponsor. The investigators should follow their hospital policy/local government policy of the 
country for the management of pa tient visits to the hospital. 
Where applicable, the study dosing will occur only if  the clinical assessment and local laboratory 
test values (that must be available before st udy dosing) have been reviewed and found to be 
acceptable per protocol guidelines. 
8.1. Screening Assessments 
Screening evaluations will be performed within  3 days before the study drug administration 
(Appendix 1). Patients who agree to participate wi ll sign the ICF before undergoing any 
study-specific screening assessment. The screening pe riod begins on the first day that a screening 
assessment is conducted. The investigator is to assess patient eligibility according to the latest 
screening assessment results. Rescreening is not allowed. 
Results of laboratory tests (Section 8.2.3) performed before informed consent has been obtained 
DQG¬î  3 days before the screening visit can be used for the purposes of screening. 
For the description of assessments that are conducted during screening as well as throughout the 
study, refer to Safety Assessments (Section 8.2) section. 
8.1.1.  Demographic Data, Medical History, and Prior Medications 
Demographic data will include age or year  of birth, gender, and race/ethnicity.  
Medical history includes any history of clinica lly significant disease or surgery history; 
reproductive status (ie, of childbeari ng potential or no childbearing potential). 
All medications (eg, prescription drugs, over-the-counter drugs, herbal medications) used by the patient within 30 days prior to the single study dose will be recorded. 
8.1.2.  Review of SARS-CoV-2 Test Result 
At screening, the investigator should review the positive results of SARS-CoV-2 test (RT-PCR 
or other tests authorized by local regul atory authorities) to confirm eligibility.  
8.2. Safety Assessments 
8.2.1.  Vital Signs 
9LWDOVLJQVZLOOLQFOXGHPHDVXUHPHQWVRIERG\WHPSHUDWXUH√õ& SXOVHUDWH respiratory rate, 
SpO 2, and blood pressure (systolic and diastolic). Puls e rate and blood pressure will be measured 
while the patient is in a seated or supine position after resting for 10 minutes. The monitoring 
frequency is detailed in Appendix 1 . 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 38 Height will be measured at screening only and wei ght will be measured before the single dose of 
study drug on Day 1. The data of height an d weight will be recorded in the eCRF. 
8.2.2.  Physical Examinations 
During the Screening Visit, a complete physical examination will be conducted, including 
evaluations of 1) head, eyes, ears, nose, and throat; 2) cardiovascular; 3) dermatological; 
4) musculoskeletal; 5) respiratory; 6) gastro intestinal; and 7) neurological systems. Any 
abnormality identified during screening will be graded according to NCI-CTCAE Version 5.0 
and recorded in the eCRF with appropriate disease/condition terms.  
At subsequent visits (and as clinically indicated), limited, symptom-directed physical 
examinations will be performed. New or worsened clinically significant abnormalities are to be 
recorded as AEs in the eCRF. Refer to Section 9.3 regarding AE definitions and reporting and 
follow-up requirements. 
8.2.3.  Laboratory Safety Tests 
Local laboratory assessments of clinical chemistry,  hematology, coagulation, and urinalysis will 
be conducted as outlined in Appendix 3 per the timepoints shown in Appendix 1 . 
Samples for pregnancy testing will also be assessed. Urine pregnancy test using highly sensitive 
human chorionic gonadotropin will be performed in all women of childbearing potential per the 
timepoints specified in Appendix 1. A confirmation serum pregnancy test must be performed if 
the urine pregnancy test is positive or equivocal. Serum pregnancy tests may be substituted for 
urine pregnancy tests if the site is not able to perform urine testing. 
Additional tests may be performed at any time during the study as determined necessary by the 
investigator or required by local regulations.  
8.2.4.  Electrocardiograms 
A 12-lead ECG will be performed at each timepoint specified in Appendix 1. For safety 
monitoring purposes, the investigator must revi ew, sign, and date all ECG tracings. Paper or 
electronic copies of ECG tracings will be kept as part of the patient‚Äôs permanent study file at the 
site. 
All ECGs are to be obtained before other assessments scheduled at that same time (eg, vital sign 
measurements, blood draws). The patient should re st in a semirecumbent or supine position for 
¬ï 10 minutes in the absence of environmental dist ractions that may induce changes in heart rate 
(eg, television, radio, conversa tion) before each ECG collection. 
8.2.5.  Adverse Events 
AEs will be graded and recorded throughout the study according to NCI-CTCAE Version 5.0. 
Characterization of toxicities will include severity, duration, and time to onset.  
All AEs, including SAEs, will be collected as described in Section 9.6. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 39 8.3. Efficacy Assessment 
8.3.1.  Viral Load 
The nasopharyngeal swab, saliva, and blood samples will be collected at the timepoints shown in 
Appendix 1. The samples will be tested by the method of RT-qPCR in a central laboratory for 
the quantitative detection of nucleic acid from SARS-CoV-2.  
To obtain nasopharyngeal swab samples, insert minitip swab with a flexible shaft (wire or 
plastic) through the nostril parallel to the palate (not upwards) until resistance is encountered or 
the distance is equivalent to that from the ear to the nostril of the patient, indicating contact with the nasopharynx. Swab should reach depth equal to  distance from nostrils to outer opening of the 
ear. Gently rub and roll the swab. Leave swab in place for several seconds to absorb secretions. 
Slowly remove swab while rotating it. Specimens  can be collected from both sides using the 
same swab, but it is not necessary to collect specimens from both sides if the minitip is saturated 
with fluid from the first collection. If a deviated septum or blockage create difficulty in obtaining 
the specimen from one nostril, use the same swab  to obtain the specimen from the other nostril. 
The process to collect saliva samples is defined in the laboratory manual. 
8.3.2.  WHO 8-Point Ordinal Scale 
WHO 8-point ordinal scale will be used to assess clinical status of patients, at timepoints 
specified in Appendix 1  
Descriptor  Score 
No clinical or virological evidence of infection 0 
No limitation of activities  1 
Limitation of activities  2 
Hospitalized, no oxygen therapy 3 
Oxygen by mask or nasal prongs 4 
Non-invasive ventilation or high-flow oxygen  5 
Intubation and mechanical ventilation 6 
Ventilation and additiona l organ support-pressors, renal replacement 
therapy (RRT), extracorporeal membrane oxygenation (ECMO) 7 
Death  8 
 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 40 8.3.3.  COVID-19-Related Symptoms and Disease Severity 
Investigators will assess if patients have r ecovered from COVID-19 based on symptoms. The 
COVID-19-related symptoms include, but are not  limited to fever, cough, diarrhea, dizziness, 
rhinorrhea, anosmia, dysgeusia, sore throat, abdominal pain, anorexia, and vomiting. The 
assessments will be performed at the timepoints specified in Appendix 1.  
Investigator will assess the disease severity at each visit: 
Mild COVID-19  
x Positive testing by standard RT-PCR assay or equivalent test  
x Symptoms of mild illness with COVID-19 that could include fever, cough, sore throat, 
malaise, headache, muscle pain , gastrointestinal symptoms, without shortness of breath or 
dyspnea  
x No clinical signs indicative of Moderate, Severe, or Critical Severity  
Moderate COVID-19  
x Positive testing by standard RT-PCR assay or equivalent testing  
x Symptoms of moderate illness with COVID-19, which could include any symptom of 
mild illness or shortness of breath with exertion 
x Clinical signs suggestive of moderate illness with COVID-19, such as respiratory rate 
¬ï 20 breaths per minute, saturation of oxygen (SpO 2) > 93% on room air at sea level, 
KHDUWUDWH¬ïEHDWVSHUPLQXWH  
x No clinical signs indicative of Severe or Critical Illness Severity  
Severe COVID-19 
x Positive testing by standard RT-PCR assay or an equivalent test  
x Symptoms suggestive of severe systemic illness with COVID-19, which could include 
any symptom of moderate illness or shortness of breath at rest, or respiratory distress  
x Clinical signs indicative of severe systemic  illness with COVID-19, such as respiratory 
UDWH¬ïSHUPLQXWHKHDUWUDWH¬ïSHUPLQXWH6S2 2 ¬îRQURRPDLUDWVHDOHYHORU
PaO 2/FiO 2 < 300  
Note: For high altitude areas, PaO 2/FiO 2 ratio should be adjusted using formula: 
PaO 2/[FiO 2√ó(barometric pressure/760)]  
x No criteria for Critical Severity  
Critical COVID-19 
x Positive testing by standard RT-PCR assay or equivalent test  
x Evidence of critical illness, defined by at least one of the following:  
‚Äì Respiratory failure defined based on resource  utilization requiring at least one of the 
following:  
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 41 ¬ÉEndotracheal intubation and mechanical ve ntilation, oxygen delivered by high-flow 
nasal cannula (heated, humidified, oxygen deliv ered via reinforced nasal cannula at 
IORZUDWHV!/PLQZLWKIUDFWLRQRIGHOLYHUHGR[\JHQ¬ï QRQLQYDVLYHSRVLWLYH
pressure ventilation, ECMO, or clinical diagnosis of respiratory failure (ie, clinical need 
for one of the preceding therapies, but preceding therapies not able to be administered in setting of resource limitation)  
‚Äì Shock (defined by systolic blood pressure < 90 mmHg, or diastolic blood pressure 
< 60 mmHg or requiring vasopressors)  
‚Äì Multi-organ dysfunction/failure  
8.4. Pharmacokinetic Assessment and Antidrug Antibody Testing 
Blood will be collected to characterize the PK of BGB-DXP593 concentrations using validated 
immunoassays. Blood samples will be collected for characterization of ADAs. Validated 
screening and confirmatory assays will be empl oyed to detect ADAs in the samples. Samples 
collected for analyses of blood concentration may also be used to evaluate safety or efficacy 
aspects related to concerns arising during or after the study. 
Blood sampling for PK and ADA will be colle cted at the timepoints specified in Appendix 2. 
Refer to the laboratory manual for instructions re garding sample collection, handling, labeling, 
storage, and shipping of laboratory samples. The actual time of each sample collected will be 
captured to the nearest minute in the eCRF and recorded in the database. 
8.5. Biomarkers 
Peripheral blood and/or saliva sa mples will be collected from patients at different timepoints 
specified in the Schedule of Assessments ( Appendix 1) to explore the association of biomarkers 
with the efficacy of BGB-DXP593, including but not limited to, SARS-CoV-2 mutations, 
serology, cytokines and ge ne expression signatures. 
Saliva samples will be collected at various time points for testing SARS-CoV-2 mutations to 
explore the association of potential mutations on the genomic region of the virus with the 
efficacy of BGB-DXP593. 
Blood samples will be collected from patients on  Day 1 before study drug administration for 
measurement of SARS-CoV-2 serology levels at baseline. Additional blood  samples will also be 
collected at various timepoints before and after study drug administration for the measurement of 
potential biomarkers in peripheral blood includi ng but not limited to cytokines and gene 
expression levels, for the exploration of the association of these biomarkers with the efficacy of 
BGB-DXP593. 
Shipping, storage, and handling of blood or saliva samples for the assessment of biomarkers will 
be managed through a central laboratory. Refer to  the laboratory manual for details of sample 
handling and the Schedule of Assessments ( Appendix 1 ) for sample collection timepoints. 
Blood samples will be individually processed and stored as described in the laboratory manual. 
Coded archival samples may be used for additional  medical and/or scientific research that are 
outside of the current study purpose and objective s (but always in compliance with applicable 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 42 law). The research may relate to the diseases that are the subject of this study, validation of new 
techniques/assays, and/or associated potential me dicines. This may include research to help 
developing ways to detect, monitor, or treat the target disease of this study. 
8.6. Visit Windows 
A visit window of ¬± 1 day is allowed for visits at  Day 5, Day 8, and Day 15, ¬± 2 days is allowed 
for visits at Day 22 and Day 29, ¬± 3 days is allowed for visits at Day 57 and Day 85, and 
¬± 7 days is allowed for visits at Day  113 ( Appendix 1 and Appendix 2). All assessments will be 
performed on the day of the specified visit unless an acceptable time window is specified. 
8.7. Unscheduled Visits 
Unscheduled visits may be performed at any time at the patient‚Äôs or the investigator‚Äôs request. 
The date and reason for the unscheduled visit mu st be recorded in the source documentation. 
If an unscheduled visit is necessary to assess toxicity, then diagnostic tests may be performed 
based on the investigator‚Äôs assessment as appropr iate, and the results of these tests should be 
entered on the unscheduled visit eCRF. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 43 9. SAFETY MONITORING AND REPORTING 
The investigator is responsible for the monitoring and documentation of events that meet the 
criteria and definition of an AE or SAE as provided in this protocol. 
9.1. Risks Associated With BGB-DXP593 
No clinical data are available yet and no risk associated with BGB-DXP593 has been identified. 
No treatment-related toxicity was noted in monkeys  at weekly repeated doses up to 300 mg/kg in 
the 14-day repeat dose study in monkeys. 
9.2. General Plan to Manage Safety Concerns 
9.2.1.  Eligibility Criteria 
Eligibility criteria were selected to guard the sa fety of patients in this study. Results from the 
nonclinical toxicology studies with BGB-DXP593, as well as the nonclinic al/clinical data from 
other SARS-CoV-2 neutralizing mA bs were considered. Patients w ith any history of a severe 
allergic reaction that has a reasonable risk of recurrence are excluded from the study (see 
Section 4.2 for the full list of exclusion criteria). 
9.2.2.  Safety Monitoring Plan 
Safety will be evaluated in this study through the monitoring of all AEs, defined and graded 
according to NCI-CTCAE Version 5.0.  
All enrolled patients will be evaluated clinically and with standard laboratory tests at regular 
intervals during their participation in this study. Safety evaluations will consist of medical interviews, recording of AEs (see Section 9.6), physical examinations, laboratory measurements 
(hematology, clinical chemistry, etc), and other assessments including those listed in 
Appendix 1. 
Administration of the study drug will be perf ormed in a setting where emergency medical 
equipment and staff who are trained to res pond to medical emergencies are available (for 
additional information, see Section 5.2). 
Blood samples will be drawn for determination of ADAs to BGB-DXP593 in patients who have 
received the study drug.  
Investigators are instructed to report a ll AEs (includes pre gnancy-related AEs). 
The potential safety issues anticipated in this st udy, as well as measures intended to avoid or 
minimize such toxicities, are outlined in Section 9.7. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 44 9.3. Adverse Events 
9.3.1.  Definitions and Reporting 
An AE is defined as any unfavorable and uni ntended sign (including an abnormal laboratory 
finding), symptom, or disease (new or exacerbated)  temporally associated with the use of a study 
drug, whether considered related to the study drug or not. 
Examples of AEs include:  
x Worsening of a chronic or intermittent pr e-existing condition, including an increase in 
severity, frequency, duration, and/or has an association with a significantly worse 
outcome 
x Detection or diagnosis of a new condition af ter study drug administration even though the 
condition might have been present before the start of the study 
x Signs, symptoms, or the clinical sequelae of a suspected interaction 
x Signs, symptoms, or the clinical sequelae of a suspected incorrect administration of either 
study drug or a concurrent medication 
When an AE or SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospital progress notes, laborato ry results, and diagnostics reports) relative to 
the AE or SAE. The investigator will then record all relevant information regarding an AE or SAE in the eCRF. However, there may be instances when copies of medical records for certain cases are requested by the sponsor. In this instance , all patient identifiers will be blinded on the 
copies of the medical records before submission to the sponsor. 
9.3.2.  Assessment of Severity 
The investigator will assess the severity for each AE and SAE reported during the study. AEs 
and SAEs should be assessed and graded based upon NCI-CTCAE Version 5.0. 
Toxicities that are not specified in NCI-CTCAE will be defined as follows: 
x Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated 
x Grade 2: Moderate; minimal, local, or noninvasive intervention indicated; limiting 
age-appropriate instrumental activities of daily living 
x Grade 3: Severe or medically significant  but not immediately life-threatening; 
hospitalization or prolongation of hospitaliza tion indicated; disabling; limiting self-care 
activities of daily living 
x Grade 4: Life-threatening consequenc es; urgent intervention indicated 
x Grade 5: Death related to AE 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 45 Note: The terms ‚Äúsevere‚Äù and ‚Äúserious‚Äù are not synonymous. Severity is a measure of intensity 
(eg, grade of a specific AE, mild [Grade 1], moderate [Grade 2], severe [Grade 3], or 
life-threatening [Grade 4]); whereas, seriousness is classified by the criteria based on the regulatory definitions. Seriousness serves as the guide for defining regulatory reporting 
obligations from the sponsor to applicable re gulatory authorities as described in Section 9.6.2 . 
9.3.3.  Assessment of Causality 
The investigator is obligated to assess the re lationship between the study drug and the occurrence 
of each AE or SAE using best clinical judgment. Alternative causes, such as natural history of 
the underlying diseases, concomitant therapy, other risk factors, and the temporal relationship of 
the AE or SAE to the study drug should be considered and investigated. The investigator should 
consult the BGB-DXP593 Investigator‚Äôs Brochure  in the determination of his/her assessment. 
There may be situations when an SAE has occurred and the investigator has only limited information to include in the initial report to the sponsor. However, it is very important that the 
investigator always assesses causality for every SAE before transmission of the SAE report to 
the sponsor because the causality assessment is 1 of the criteria used when determining 
regulatory reporting requirements. The investigator  may subsequently cha nge his/her opinion of 
causality considering follow-up information and may amend the SAE report accordingly. 
The causality of each AE should be assessed and cl assified by the investigator as ‚Äúrelated‚Äù or 
‚Äúnot related‚Äù based on all information available at the time of reporting. An AE is considered 
related if there is ‚Äúa reasonable possibility‚Äù that the AE may have been caused by the study drug (ie, there are facts, evidence, or arguments to suggest possible causation). A number of factors 
should be considered in making this assessment, including: 
x Temporal relationship of the AE to the administration of study treatment/study procedure 
x Whether an alternative etiology has been identified 
x Mechanism of action of the study drug 
x Biological plausibility 
x An AE should be considered ‚Äúrelated‚Äù to study  drug if any of the following criteria are 
met; otherwise, the event should be assessed as ‚Äúnot related‚Äù: 
 There is clear evidence to suggest a causal relationship, and other possible 
contributing factors can be ruled out 
 There is evidence to suggest a causal relationship, and the influence of other factors is unlikely 
 There is some evidence to suggest a causal relationship (eg, the AE occurred within a reasonable time after administration of the study drug). However, the 
influence of other factors may have cont ributed to the AE (eg, the patient‚Äôs 
clinical condition or other concomitant AEs). 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 46 9.3.4.  Follow-up of Adverse Events 
After the initial AE or SAE report, the investigator is required to proactively follow each patient 
and provide further information to th e sponsor on the patient‚Äôs condition. 
All AEs and SAEs documented at a previous visit/contact and designated as ongoing will be 
reviewed at subsequent visits/contacts. 
All AEs and SAEs will be followed until resolu tion, the condition stabilizes or is considered 
chronic, the AE or SAE is otherwise explained, th e patient is lost to follow-up, or the patient 
withdraws consent. The investigator will en sure that follow-up includes any supplemental 
investigations as may be indicated to elucidate the nature and/or causality of the AE or SAE. 
This may include additional labor atory tests or investigations, histopathological examinations, 
radiographic imaging, or consultation w ith other health care professionals. 
The sponsor may request that the investigator perform or arrange for the conduct of supplemental measurements and/or evaluations to elucidate as fully as possible the nature and/or causality of 
the AE or SAE. The investigator is obligated to assist. If a patient dies during participation in the study or during a recognized follow-up period, the sponsor will be provided with a copy of any 
postmortem findings, including histopathology. 
New or updated information should be reported to the sponsor according to the SAE instructions 
provided by the sponsor within the timeframes outlined in Section 9.6.2. 
9.3.5.  Laboratory Test Abnormalities 
Abnormal laboratory findings (eg, clinical che mistry, complete blood count, coagulation, or 
urinalysis) or other abnormal assessments (eg, ECGs or vital signs) that are judged by the investigator as clinically significant will be recorded as AEs or SAEs. This includes clinically 
significant abnormal laboratory findings or othe r abnormal assessments that are present at 
baseline and significantly worsen during the study. The definition of clinically significant is left 
to the judgment of the investigator. In general, these are the laboratory test abnormalities or other 
abnormal assessments that: 
x are associated with clinical signs or symptoms, or  
x require active medical intervention, or  
x lead to treatment interruption or discontinuation, or 
x require close observation, more frequent fo llow-up assessments, or further diagnostic 
investigation. 
If a clinically significant laboratory abnormality is  a sign of a disease or syndrome (eg, alkaline 
phosphatase and bilirubin 5 x ULN associated with cholestasis), only the diagnosis 
(ie, cholestasis) should be recorded on the AE eCRF. 
If the laboratory abnormality can be characterized  by a precise clinical term per standard 
definitions, the clinical term should be recorded as the AE. For exampl e, an elevated serum 
potassium level of 7.0 mEq/L should be recorded as ‚Äúhyperkalemia.‚Äù 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 47 Observations of the same clinically significant laboratory abnormality from visit to visit should 
not be repeatedly recorded on the AE eCRF, unles s the etiology changes. The initial severity of 
the event should be recorded, and the severity  or seriousness should be updated any time the 
event worsens. 
9.4. Definition of a Serious Adverse Event 
An SAE is any untoward medical occurrence that, at any dose: 
x Results in death 
x Is life-threatening 
Note: The term ‚Äúlife-threatening‚Äù in the definition of ‚Äúserious‚Äù refers to an AE in which the patient was at risk of death at the time of the AE. It does not refer to an AE that hypothetically might have cause d death if it was more severe. 
x Requires hospitalization or prolonga tion of existing hospitalization 
Note: In general, hospitalization signifies that the patient was admitted (usually involving at least an overnight stay) to the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the physician‚Äôs 
office or outpatient setting. 
x Results in disability/incapacity 
Note: The term ‚Äúdisability‚Äù means a substantial disruption of a person‚Äôs ability to 
conduct normal life functions. This definition is not inte nded to include experiences 
of relatively minor medical significance, such as uncomplicated headache, nausea, 
vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle), which may 
interfere with or prevent everyday life func tions but do not constitute a substantial 
disruption. 
x Is a congenital anomaly/birth defect 
x Is considered a significant medical AE by the investigator based on medical judgement 
(eg, may jeopardize the patient or may requi re medical/surgical intervention to prevent 
one of the outcomes listed above) 
The following are NOT considered to be SAEs: 
x Hospitalization for elective treatment of a pre-existing condition that did not worsen from 
baseline 
x Hospitalization for social/c onvenience considerations 
x Scheduled therapy for the target disease of the study, including admissions for PK 
sampling or convenience 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 48 9.5. Suspected Unexpected Serious Adverse Reaction 
A suspected unexpected serious adverse reacti on is a serious adverse reaction that is both 
unexpected (ie, not present in the study drug‚Äôs reference safety information) and meets the 
definition of a serious adverse drug reaction, the sp ecificity or severity of which is not consistent 
with those noted in the BGB-DXP593 Investigator‚Äôs Brochure . 
9.6. Timing, Frequency, and Method of Capturing Adverse Events and 
Serious Adverse Events 
9.6.1.  Adverse Event Recording Period 
After informed consent has been signed but befo re the administration of the study drug, only 
SAEs should be reported. 
After initiation of the study drug, all AEs and SAEs, regardless of relationship to study drug, will 
be reported until 30 days after study treatment or  End-of-Study Visit, whic hever is later. After 
the period, the investigator should report any SAEs that are considered to be related to the study 
drug. 
For the follow-up period for AEs, see Section 9.3.4. 
9.6.2.  Reporting Serious Adverse Events 
9.6.2.1.  Prompt Reporting of Serious Adverse Events 
As soon as the investigator determines that an AE meets the protocol definition of an SAE, the 
event must be reported promptly (within 24 hours)  to the sponsor or designee as described in 
Table 2.  
Table 2: Timeframes and Documentation Methods for Reporting Serious Adverse 
Events to the Sponsor or Designee 
 Timeframe for 
sending initial report Documentation method Timeframe for sending follow-up report Documentation method Reporting method 
All SAEs Within 24 hours 
of first 
knowledge of the SAE SAE report As expeditiously 
as possible SAE report Email or fax SAE report form 
Abbreviations: SAE, serious adverse event. 
9.6.2.2.  Completion and Transmission of the Serious Adverse Event Report 
Once an investigator becomes aware that an SAE ha s occurred in a patient, he/she is to report the 
information to the sponsor within 24  hours, as outlined above in Section 9.6.2.1 . The SAE report 
will always be completed as thoroughly as possibl e, including all available details of the event 
and forwarded to the sponsor or desi gnee within the de signated timeframes. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 49 If the investigator does not have all information regarding an SAE, he/she is not to wait to 
receive additional information before notifyi ng the sponsor or designee of the SAE and 
completing the form. The form will be update d when additional information is received. 
The investigator must always provide an assessment of causality for each SAE as described in 
Section 9.3.3. 
The sponsor will provide contact information for SAE receipt. 
9.6.2.3.  Regulatory Reporting Requirements for Serious Adverse Events 
The investigator will report all SAEs to the spons or in accordance with the procedures detailed in 
Section 9.6.2.1 . The sponsor has a legal responsibility to  notify, as appropriate, both the local 
regulatory authority and other regulatory agenci es about the safety of a drug under clinical 
investigation. 
The investigator, or responsible person according to local requirements, will comply with the 
applicable local regulatory requirements related to  the reporting of SAEs to regulatory authorities 
and the IRB/IEC. All suspected unexpected serious advers e reactions (as defined in Section 9.5) will be submitted 
to all applicable regulatory authorities and investigators for BGB-DXP593 studies. 
When a study center receives an initial or follow-up safety report or other safety information 
(eg, revised Investigator‚Äôs Brochure) from the s ponsor, the investigator or designated responsible 
person is required to promptly notify his/her IRB or IEC. The investigator should place copies of 
safety reports from the sponsor in the investigator site file. 
9.6.3.  Eliciting Adverse Events 
The investigator or designee will ask patients about AEs by asking the following standard 
questions: 
x How are you feeling? 
x Have you had any medical problems since your last visit? 
x Have you taken any new medici nes since your last visit? 
9.6.4.  Deaths 
Death is an outcome and not usually considered an  AE. If the only information available is death 
and the cause of death is unknown, then the death is reported as an AE (eg, ‚Äúdeath,‚Äù ‚Äúdeath of 
unknown cause,‚Äù or ‚Äúdeath unexplained‚Äù). 
9.6.5.  Recording Pregnancies 
If a female patient or the partner of a male patie nt becomes pregnant within 30 days after the 
single dose of study drug, a pregnancy report fo rm must be completed and expeditiously 
submitted to the sponsor to facilitate outcome follow-up. Information on the status of the mother 
and child will be forwarded to the sponsor. Ge nerally, follow-up will be no longer than 6 to 
8 weeks following the estimated delivery date. Any premature termination of  the pregnancy will 
be reported. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 50 While pregnancy itself is not considered to be  an AE, any pregnancy complication or elective 
termination of a pregnancy for medical reasons  will be recorded as an AE or SAE. 
An abortion, whether accidental, therapeutic, or spontaneous, should always be reported as an 
SAE. Similarly, any congenital anomaly/birth defect in a child  born to a patient exposed to the 
study drug should be recorded and reported as an SAE. 
9.6.6.  Expedited Reporting to Health Authorities, Investigators, Institutional Review 
Boards, and Independent Ethics Committees 
The sponsor will promptly assess all SAEs against cumulative study drug experience to identify and expeditiously communicate new safety findin gs to regulatory authorities, investigators, 
IRBs, and IECs based on a pplicable legislation. 
To determine the reporting requirements for individual SAEs, the sponsor will assess the 
expectedness of the SAEs using the following reference safety information documents: 
x BGB-DXP593 Investigator‚Äôs Brochure  
9.6.7.  Recording Infusion-R elated Reactions 
The symptoms of infusion-related reactions may include but are not limited to fever, chills/rigor, nausea, pruritus, angioedema, hypotension, headach e, bronchospasm, urticaria, rash, vomiting, 
myalgia, dizziness, or hypertension. Severe re actions may include acute respiratory distress 
syndrome, myocardial infarction, ventricu lar fibrillation, or cardiogenic shock.  Individual signs 
and symptoms of an infusion reaction should be recorded each as a separate AE in the eCRF and identified as an infusion-related reaction. Refer to the eCRF completion guidelines for details. 
9.7. Management of Infusion-Related Reactions and Severe 
Hypersensitivity 
As a routine precaution, following completion of study drug(s) administration, patients must be monitored for at least 2 hours after the infusion of study drug in a setting where emergency medical equipment and staff who are trained to respond to medical emergencies are available. 
The management for infusion-rela ted reactions, and severe hypersensitivity reactions, according 
to the NCI-CTCAE criteria are outlined in the following subsections. 
9.7.1.  Managing Infusion-Related Reactions 
The symptoms of infusion-related reactions include but are not limited to fever, chills/rigor, 
nausea, pruritus, angioedema, hypotension, headache, bronchospasm, urticaria, rash, vomiting, myalgia, dizziness or hypertension. Severe re actions may include acute respiratory distress 
syndrome, myocardial infarction, ventricu lar fibrillation, and cardiogenic shock. 
Patients should be closely monitored for infusion -related reactions. Immediate access to an ICU 
or equivalent environment and appropriat e medical therapy (including epinephrine, 
corticosteroids, intravenous antihistamines, br onchodilators, and oxygen) mu st be available to 
treat infusion-related reactions. 
Treatment modifications for symptoms of infusion-related reactions due to study drug(s) are 
provided in Table 3 . 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 51 Table 3: Treatment Modifications for Symptoms of Infusion-Related Reactions Due to 
Study Drug 
NCI-CTCAE grade Treatment modification for Study Drug 
Grade 1 - mild 
Mild transient reaction; infusion interruption not 
indicated; intervention not indicated. Decrease infusion rate by 50%. Any worsening is 
closely monitored. Medical management as needed.  
Grade 2 - moderate 
Therapy or infusion interruption indicated but responds 
promptly to symptomatic treatment (eg, antihistamines, nonsteroidal anti-inflammatory drugs, narcotics, 
intravenous fluids); prophylactic medications indicated IRU¬î  24 hours. Stop infusion. Infusion may be resumed at 50% of previous rate once infusion-related reaction has resolved or decreased to Grade 1 in severity within 2 hours of the infusion interruption. The patient should 
be discontinued from study drug if the Grade 2 infusion-related reaction has not resolved or decreased 
over 2 hours of the infusion interruption.
 Any 
worsening is closely monitored. Proper medical 
management should be instituted as described below.  
Grade 3 ‚Äì severe 
Prolonged (eg, not rapidly responsive to symptomatic 
medication and/or brief interruption of infusion); recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae. Immediately stop the infusion. Proper medical management should be instituted as described below. 
The patient should be withdrawn from study drug 
treatment. 
Grade 4 ‚Äì life-threatening 
Life-threatening consequences; urgent intervention indicated. Immediately stop the infusion. Proper medical management should be instituted as described below. 
The patient should be withdrawn from study drug 
treatment. 
Hospitalization is recommended. 
Abbreviations: NCI-CTCAE, National Cancer Institute-Common Terminology Criteria for Adverse Events. 
NCI-CTCAE Grade 1 or 2 infusion reaction: Proper medical mana gement should be 
instituted, as indicated per the type of reaction. This includes but is not limited to an 
antihistamine (eg, diphenhydramine or equivalent), antipyretic (eg, paracetamol or equivalent), 
and, if considered indicated, oral or intrave nous glucocorticoids, epin ephrine, bronchodilators, 
and oxygen. 
NCI-CTCAE Grade 3 or 4 infusion reaction: Proper medical ma nagement should be instituted 
immediately, as indicated per type and severity of  the reaction. This includes but is not limited to 
oral or intravenous antihistamines, antipyretics,  glucocorticoids, epine phrine, bronchodilators, 
and oxygen. 
9.7.2.  Severe Hypersensitivity Reactions 
If hypersensitivity reaction occurs, the patient must  be treated according to the best available 
medical practice as described in the complete gu ideline for emergency tr eatment of anaphylactic 
reactions according to the Working Group of  the Resuscitation Council (United Kingdom) 
(Soar et al 2008 ). Patients should be instructed to report any delayed reactions to the investigator 
immediately. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 52 In the event of a systemic anaphylactic/anaphylactoid reaction, the infusion must be stopped 
immediately and the patient discontinued from the study. Systemic an aphylactic/anaphylactoid 
reactions typically manifest within minutes foll owing administration of the drug/antigen and are 
characterized by respiratory distress; laryngeal  edema; and/or intense bronchospasm; and are 
often followed by vascular collapse or shock without antecedent respiratory difficulty; cutaneous 
manifestations such as pruritus and urticaria with/without edema; and gastrointestinal 
manifestations such as nausea, vomiting,  crampy abdominal pain, and diarrhea. 
The patient will be administered epinephrine injection and dexamethasone infusion if 
hypersensitivity reaction is observed. The patient should then be placed on monitor immediately 
and an ICU should be alerted for possible transfer if needed. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 53 10. STATISTICAL METHODS AND SAMPLE SIZE 
DETERMINATION 
A statistical analysis plan (SAP) will be prepared and finalized prior to database lock. This 
document will provide further details regarding the definition of analysis variables and analysis methodology to address all study objec tives. Any deviations in the planned analysis as stated in 
the protocol will be delineated in the SAP. Any deviations from the SAP will be reported in the 
clinical study report. A data review will be conducted prior to database lock. 
10.1. Statistical Analysis 
10.1.1.  Analysis Sets 
The Intent-to-Treat (ITT) Analysis Set includes all randomized patients. Patients will be analyzed according to the treatment  assigned at randomization. This will be the primary analysis 
set for efficacy analyses. 
The Safety Analysis Set incl udes all patients who have rece ived the study drug (BGB-DXP593 
or placebo). Patients will be analyzed according to their actual treatment received. The Safety 
Analysis Set will be used for all safety analyses. 
The PK Analysis Set includes all patients who have received the study drug (BGB-DXP593) per 
the protocol and for whom any pos tdose PK data are available. 
The ADA Analysis Set includes all the patients wh o have received the study drug and in whom 
both baseline ADA and at least 1 postbaseline ADA results are available. 
10.1.2.  Randomization Methods 
Patients will be randomized using the IRT system with allocation ratio of 1:1:1:1 to placebo, 
BGB-DXP593 at 5 mg/kg, BGB-DXP593 at 15 mg/kg, and BGB-DXP593 at 30 mg/kg. Patient 
randomization will be stratified by country and disease severity (mild versus moderate 
COVID-19). 
10.1.3.  Patient Disposition 
The number of patients randomized, treated, disc ontinued from study drug and/or the study will 
be counted. The primary reason for study drug and/or study discontinuation will be summarized 
according to the categories in the eCRF. 
Important protocol deviations will be summarized and listed by category. 
10.1.4.  Demographic and Other Baseline Characteristics 
Demographic and other baseline characteristics wi ll be summarized using the ITT Analysis Set 
and descriptive statistics. Conti nuous variables include but are not limited to age, weight, and 
height. Categorical variables include but are not limited to gender, geographical region, and race. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 54 10.1.5.  Prior and Concomitant Medications 
Prior medications will be defined as medications that stopped before the administration of study 
drug. Concomitant medications will be defined as medications that 1) started before the 
administration of study drug and were continuing at the time of the administration of study drug, 
or 2) started on or after the date of the adminis tration of study drug up to 30 days after dosing. 
Concomitant medications will be coded using th e World Health Organization Drug Dictionary 
drug codes and will be further c oded to the appropriate Anatomic al Therapeutic Chemical code 
indicating therapeutic classification. Prior and concomitant medications will be summarized and listed by drug and drug class. A listing of prior and concomitant medications will be provided. 
10.2. 
Efficacy Analyses  
10.2.1.  Primary Endpoint Analyses 
The statistical hypotheses to be tested for the primary endpoint are as follows: 
H0: there is a flat dose response curve comparing change from baseline to Day 8 in SARS-CoV-2 
viral shedding in the placebo and the BGB-DXP593 dose groups 
H1: there is a non-flat dose response curve i ndicating a benefit of BGB-DXP593 over placebo 
A Mixed Model Repeated Measures (MMRM) analysis will be used to analyze the primary 
endpoint of change from baseline to Day 8 in SARS-CoV-2 viral shedding. This model will 
include treatment, visit, and disease severity as di screte fixed effects; baseline viral shredding as 
a continuous fixed effect; and in teraction between visit and trea tment, interactio n between visit 
and baseline, interaction between visit and diseas e severity, and patient as a random effect. The 
primary treatment comparisons will be the contrast between treatments at Day 8. 
The analysis will be carried out and covariate-ad justed fixed effect estimates of average response 
for each treatment and the covarian ce matrix will be extracted from the fit and used for multiple 
comparison procedures and modelling approaches (MCPMod) analysis. 
The primary analysis uses methodology for dose finding employing both multiple comparison 
procedures and modelling techniques. The MCPMod procedure allows for simultaneous 
evaluation of different potential dose response patt erns, whilst protecting the overall probability 
of Type I error (one- VLGHGƒÆRI  
For the hypothesis testing and for the sample size calculation, the basic shape of each of the 
models to be tested must be predefined. The following models will be considered for this 
analysis: linear, Emax, SigEmax and quadratic.  
The model assumptions and resulting graphs were selected to cover both plausible and a diverse 
range of dose response patterns. These are shown in Figure 3 . The parameters for each model 
shape are listed in Table 4 . 
 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
CONFIDENTIAL Page 55 Figure 3: Shape of the Considered Dose Re sponse Patterns for the MCPMod Analysis 
Abbreviation: MCPMod, multiple comparison procedures and modelling approaches 
Table 4: Parameter(s) in Each Model 
Model Prespecified parameters 
Emax1 ED 50   2.6 
Emax2 ED 50  12.5 
sigEmax ED 50  K    4 
Quadratic ƒØ -0.022 
Linear No assumption needed 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 56 If at least one model is statistically significant, then we will reject the null hypothesis of a flat 
dose response relationship over viral shredding cha nge at Day 8, with a multiple contrast test 
controlled for the family-wise type I error rate at one- VLGHGƒÆ   
After rejecting the null hypothesis, the statistically significant model(s) from the above candidate 
set are selected as reference models. The dose-response relationship is estimated using model average technique to generate the new estimates. 
The target dose(s) can be estimated from the average model by incorporating information on the 
minimum clinically relevant effect and by accounting for safety. 
Comparisons of active doses to placebo (90% conf idence intervals [CIs] and p-values) based on 
the mixed effects model will be reported. These are supportive analyses of the primary endpoint 
to supplement the MCPMod analysis, which is the primary analysis. 
10.2.2.  Secondary Endpoint Analyses 
Secondary efficacy endpoints will include: 
x Time-weighted average change in viral shedding as measured by RT-qPCR in 
nasopharyngeal swab samples from baseline to Day 15 
x Change in SARS-CoV-2 viral shedding as measured by RT-qPCR in nasopharyngeal swab samples from baseline to Day 15 
x Time to negative RT-qPCR in all tested samples with no subsequent positive RT-qPCR in any tested samples 
x Proportion of patients requiring hospitalization due to worsened COVID-19 
x Time to resolution of all COVID-19-related symptoms 
x All-cause mortality rate at Day 29 
The time-weighted average change in viral shedding as measured by RT-qPCR in 
nasopharyngeal swab samples from ba seline to Day 15 is defined as: 
œÉ [0.5 √ó (‹ª
‡Øú+‹ª‡Øú‡¨æ‡¨µ)√ó(›ê‡Øú‡¨æ‡¨µ‡µÜ›ê‡Øú)]‡Øï‡¨ø‡¨µ
‡Øú‡≠Ä‡Øî
›ê‡Øï‡µÜ›ê‡Øî 
where ‹ª‡Øú is the change from baseline in viral shedding at Visit ›Ö ,›ê is the time at the specified 
timepoint (the actual study day), ‹Ω is the baseline assessment at Day 1, and ‹æ is the last 
assessment at or prior to Day 15 visit. An alysis of covariance (ANCOVA) model with 
corresponding baseline viral shedding, disease severity , and treatment as covariates will be used. 
Comparisons of active doses to placebo (90% CIs and p-values) will be provided.  
The same MMRM analysis for primary endpoint will be used to analyze the change in SARS-
CoV-2 viral shedding from baseline to Day 15. Comparisons of active doses to placebo (90% CIs 
and p-values) will be provided. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 57 Kaplan-Meier method will be used to assess the time to negative RT-qPCR. The corresponding 
quartiles (including the median) will be reporte d and a two-sided 95% CI of median, if 
estimable, will be constructed with a generalized Brookmeyer  and Crowley method for each 
dosing group. Patients who have died  prior to experiencing the event of interest will be censored 
on the day of data cutoff. 
The number of patients who require hospitalizati on due to worsened COVID-19 will be counted. 
Corresponding proportion will be derived and a tw o-sided binomial exact 95% CI of proportion 
will be constructed.  Kaplan-Meier method will be used to assess the time to resolution of all COVID-19-related 
symptoms. The corresponding quartiles (including the median) will be reported and a two-sided 
95% CI of median, if estimable, will be constr ucted with a generalized Brookmeyer and Crowley 
method for each dosing group. Patients who have died  prior to experiencing the event of interest 
will be censored. Their follow-up length will be arbitrarily set as (data cutoff date ‚Äì first-patient-in date). This approach is to c ount death as the worst possible outcome without 
possibility of recovery. 
Kaplan-Meier method will be used to assess  all-cause mortalities and corresponding quartiles 
(including the median) will be reported. A two-si ded 95% CI of median, if estimable, will be 
constructed with a generalized Brookmeyer and Crowley method. Patients who does not die will 
be censored on the last known date alive.  
10.2.3.  Exploratory Endpoint Analyses 
Version .0 VV-CLIN-073998 1

BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
CONFIDENTIAL P a
ge 58 Safety will be determined by monitoring AE s and laboratory values (hematology, clinical 
chemistry, coagulation, and urinalysis). Vita l signs, physical examinations, and ECG findings 
will also be used in determining the safety profile . The severity of AEs will be graded according 
to NCI-CTCAE Version 5.0. The incidence of TEAEs will be reported as the number 
(percentage) of patients with TEAEs by Medi cal Dictionary for Regulatory Activities 
(MedDRA) system organ class and preferred term . Descriptive summary statistics (eg, n, mean, 
standard deviation, median, minimum, and maximum for con tinuous variables; n [%] for 
categorical variables) and changes from baseline will be determined for laboratory parameters and vital signs. 
Safety data will be summarized using the Safety Analysis Set. 
10.3.1.  Extent of Exposure 
Extent of exposure to each study drug will be summarized descriptively for the total dose 
received per patient (mg) and relative dose intensity. 
The number (percentage) of patients requiring treatment interruption because of AEs will be 
summarized for each study drug. Reasons for dose interruption will be summarized as well. 
Patient data listings will be pr ovided for all dosing records and fo r calculated summary statistics.  
10.3.2.  Adverse Events 
The AE verbatim descriptions (investigator‚Äôs description from the eCRF) will be coded using 
MedDRA. AEs will be coded to MedDRA lowest level term, preferred term, and primary system organ class. 
A TEAE is defined as an AE that had an onset date or a worsening in severity from baseline 
(pretreatment) on or after the administration of study drug and up to the 30 days after dosing. 
The incidence of TEAEs will be reported as the number (percentage) of patients with TEAEs by 
system organ class and preferred term. A patie nt will be counted only once by the highest 
severity grade per NCI-CTCAE Version 5.0 within a system organ class and preferred term, even 
if the patient experienced more than 1 TEAE within a specific system organ class and preferred term. The number (percentage) of patients with TEAEs will also be summarized by relationship 
to the study drug. 
Treatment-related TEAEs include those events considered by the investigator to be related to 
VWXG\WUHDWPHQWRUZLWKPLVVLQJD VVHVVPHQWRIWKHFDXVDOUHODWL RQVKLS6$(VGHDWKV¬ï  Grade 3 
TEAEs, treatment-related TEAEs, and TEAEs that led to treatment discontinuation or treatment 
interruption will be summarized.  
Version .0 VV-CLIN-073998 1

BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 59 10.3.3.  Laboratory Analyses 
Clinical laboratory (eg, hematology, clinical chem istry, coagulation, and urinalysis) values will 
be evaluated for each laboratory parameter as a ppropriate. Abnormal laboratory values will be 
flagged and identified as those outside (above or below) the normal range. Reference (normal) 
ranges for laboratory parameters will be provided. Descriptive summary statistics (eg, n, mean, standard deviation, median, minimum, and maximum for con tinuous variables; n [%] for 
categorical variables) for laboratory parameters and their changes from baseline will be calculated. Laboratory values will be summarized by visit and by visit with the maximum 
postbaseline change. 
Laboratory parameters that are graded by NCI-CTCAE Version 5.0 or higher will be 
summarized by NCI-CTCAE grade. In the summary of laboratory parameters by NCI-CTCAE grade, parameters with NCI-CTCAE grading in both high and low directions will be summarized 
separately. 
10.3.4.  Vital Signs 
Descriptive statistics for vital sign parameters (systolic and diastolic blood pressure, pulse rate, 
and body temperature) and changes from baseline will be presented by visit for all visits. Vital signs will be listed by patient and visit. 
10.4. Pharmacokinetic Analyses 
The PK analyses will include patients with sufficient data to enable estimation of key parameters, such as C
max, tmax, t1/2, AUC t, AUC inf, AUC 0-29, CL, and V z (as appropriate for data 
collected), with patients grouped according to treatment received. Non-compartmental or 
model-based methods will be  used as appropriate. 
Individual and mean serum BGB-DXP593 concentra tion versus time data will be tabulated and 
plotted by dose level. The PK  parameters of BGB-DXP593 ma y be derived and summarized 
with descriptive statistics (sample size, mean, standard deviation, coefficient of variance, median, minimum, maximum, geometric mean, geometric coefficient of variance). Other PK 
parameters may be calculated if supported by the data. Individual serum concentration versus 
time data will be tabulated and plotted by dose level. 
Additional PK analyses (such as modeling and simulation using nonlinear mixed effects 
modelling) may be conduc ted as appropriate. 
10.5. Immunogenicity Analyses 
The immunogenicity results will be summarized us ing descriptive statistics by the number and 
percentage of patients who develop detectable ADAs. The incidence of positive ADAs and 
neutralizing ADAs will be reported for evaluable patients. The effect of immunogenicity on PK 
and safety may be eval uated if data allow. 
10.6. Other Exploratory Analyses 
Version .0 VV-CLIN-073998 1

BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 60 10.7. Sample Size Consideration 
The sample size calculation is based on the following assumptions: 
x The primary endpoint ‚Äúchange from baseline to Day 8 in SARS-CoV-2 viral shedding‚Äù is 
normally distributed 
x One-sided significance level ƒÆ   
x True maximum treatment effect size of BGB-DXP593 versus placebo is -1.5 log 10 copies 
per mL 
x Standard deviation is 3.2 log 10 copies per mL ( Wang et al 2020 ) 
x Prespecified candidate models listed in Section 10.2.1  
Forty-one patients are needed with primary endpoint  data per arm to provide at least 82% power 
to detect non-flat dose-response relationship. MCPMod approach is used. In order to ensure 
41 patients per arm with primary endpoint data, at least 43 pa tients per arm need to be 
randomized. 
The calculation has been performed using R software, version 3.6.1. 
10.8. Interim Analyses 
A primary analysis is planned after all patients  have finished Day 8 visit or discontinued the 
study earlier. A decision will be made based on th e interim results about whether a Phase 3 study 
should be initiated and which dose to be used for the Phase 3 study. 
10.9. Missing Data Handling and Censoring Rules 
In general, values for missing da ta will not be imputed, unless methods for handling missing data 
are specified.  For MMRM analysis, no imputation will be perfor med for missing viral shredding. If a patient 
misses a visit, the missing data will not be imputed. The mixed effect model will handle missing 
data based on a likelihood  method under the "missing at random‚Äù assumption.  
Sensitivity analyses using method of last observation carry forward (LOCF) may be considered 
to assess the potential impact from missing data, which will be detailed in the statistical analysis 
plan (SAP). 
Missing dates or partially missing dates will be imputed conservatively for adverse events and 
prior/concomitant medications/procedures. Specific rules for handling of missing or partially missing dates for adverse events and prior/concomitant medications/procedures will be provided 
in the statistical analysis plan (SAP). 
Censoring rules for analyses of time-to-event endpoints are determined as in Table 5 . 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 61 Table 5: Censoring Rules for Analysis of Time-to-event Endpoints 
No. Situation Date of Event or Censoring Outcome 
1 Target event documented Date of occurrence of target event Event 
2 Multiple target events documented Date of first occurrence of target event Event 
3 No target event or death occurred by the time 
of the End-of-Study Visit or the Safety Follow-
up Visit (whichever is later), or data cut-off, or 
withdrawal from study, whichever comes first Date of last adequate event assessment 
prior to or on the date of the End-of-Study Visit or the Safety 
Follow-up Visit (whichever is later), or 
data cut-off, or withdrawal from study, 
whichever comes first Censored 
4 Death and no target event prior to death Date of data cutoff Censored 
 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 62 11. STUDY COMMITTEES 
11.1. Independent Data Monitoring Committee  
An IDMC will be established; the function an d membership will be described in the IDMC 
Charter. 
Regular safety monitoring and efficacy monitoring will be performed by the IDMC. The first 
IDMC safety review will occur after at least 12 patients (ie, approximately 3 patients per 
treatment arm) have received study treatment and have been followe d up for at least 7 days. The 
frequency of the subsequent safety reviews will be defined in the IDMC Charter. Preliminary 
efficacy summaries will be provided to the IDMC when approximately 60 pa tients have received 
study treatment and have been fo llowed up for at least 14 days. Preliminary efficacy summaries 
will be included in the IDMC report and reported monthly afterwards. The frequency of the meetings may be adjusted based on the need for safety monitoring of the study. The IDMC has access to unblinded information to assess the safety and efficacy. 
In addition to the planned IDMC review(s),  ad hoc reviews may take place based on new 
information. 
The IDMC may recommend modifications to the study procedures or conduct based on available 
data. After IDMC review and discussion, the spons or will make all final decisions regarding any 
change in study conduct. Please see the details in the IDMC Charter. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 63 12. SOURCE DOCUMENTS AND ACCESS TO SOURCE 
DATA/DOCUMENTS 
The investigator must maintain adequate and accurate records to ensure that the conduct of the 
study may be fully documented. Such records include but are not limited to the protocol, protocol amendments, ICFs, and documentation of IRB/IEC and governmental approvals. In 
addition, at the end of the study, the investigator  will receive patient data, which will include an 
audit trail containing a complete reco rd of all changes to such data. 
12.1. Access to Information for Monitoring 
In accordance with International Council for Harmonisation GCP guidelines, the study monitor 
must have direct access to the investigator‚Äôs source documentation to verify the data recorded in 
the eCRFs for consistency. 
The monitor is responsible for routine review of the eCRFs at regular intervals throughout the 
study to verify adherence to the protocol and the completeness, consistency,  and accuracy of the 
data being entered on them. The monitor should have access to any patient records needed to 
verify the entries in the eCRFs. The investigator agrees to cooperate with the monitor to ensure 
that any problems detected during thes e monitoring visits are resolved. 
12.2. Access to Information for Auditing or Inspections 
Representatives of regulatory authorities or of BeiGene, Ltd., (hereafter referred to as BeiGene) may conduct inspections or audits any time during or after completion of this clinical study. If 
the investigator is notified of an inspection by a regulatory authority, the investigator agrees to 
notify the sponsor or its designee immediately. The investigator agrees to provide to representatives of a regulatory agency or BeiGene access to records, facilities, and personnel for 
the effective conduct of any inspection or audit. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 64 13. QUALITY ASSURANCE AND QUALITY CONTROL 
13.1. Regulatory Authority Approval 
The sponsor will obtain approval to conduct the study from the appropriate regulatory agency in 
accordance with any applicable country-specific re gulatory requirements or file the protocol to 
the appropriate regulatory agency before the st udy is initiated at a study center in that country. 
13.2. Quality Assurance 
To ensure compliance with GCP and all applicable regulatory requirements, the sponsor may 
conduct a quality assurance audit. Regulatory agen cies may also conduct a regulatory inspection 
of this study. Such audits/inspections can occu r at any time during or after completion of the 
study. If an audit or inspection occurs, the investigator and institution agree to allow the auditor/inspector direct access to all relevant documents and to allocate his/her time and the time 
of his/her personnel to the auditor/inspector to discuss findings and any relevant issues. 
13.3. Study Site Inspections 
This study will be organized, performed, and reporte d in compliance with the protocol, standard 
operating procedures, working practice documents, and applicable regula tions and guidelines. 
Site audits may be performed  periodically by the sponsor‚Äôs or the contract research 
organization‚Äôs qualified compliance auditing team, which is an independent function from the 
study team responsible for conduct of the study. 
Site visits will be conducted by the sponsor or an  authorized representative to inspect study data, 
patients‚Äô medical records, and eCRFs. The invest igator is to permit national and local health 
authorities; sponsor study monitors, representatives, and collaborators; and IRB/IEC members to 
inspect all facilities and records relevant to this study. 
13.4. Drug Accountability 
The investigator or designee (ie, unblinded pharm acist) is responsible for ensuring adequate 
accountability of all used and unused study drug(s). This includes acknowledgment of receipt of 
each shipment of study drug(s) (quantity and condition), patient drug dispensation records, and 
returned or destroyed study drug(s). Dispensa tion records will document quantities received from 
BeiGene‚Äôs designated depot or its designee and quantities dispensed to patients, including 
batch/lot number, date dispense d, patient identifier number, a nd the initials of the person 
dispensing the medication. 
At study initiation, the monitor will evaluate th e site‚Äôs standard operating procedure for study 
drug disposal/destruction to ensure that it complies with BeiGene requirements specified in the 
Pharmacy Manual. At appropriate times during th e conduct of the study or at the end of the study 
following final drug inventory reconciliation by  the unblinded monitor, the study site will 
dispose of and/or destroy all unused study drug supplies, including empty containers, according to these procedures. If the site cannot meet Be iGene‚Äôs requirements specified in the Pharmacy 
Manual for disposal, arrangements will be made between the site and BeiGene or its representative for destruction or return of unused study drug supplies. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 65 All drug supplies and associated documentation will be periodically reviewed and verified by the 
study unblinded monitor over the course of the study. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 66 14. ETHICS/PROTECTION OF HUMAN PATIENTS 
14.1. Ethical Standard 
This study will be conducted by the principal investigator and the study center in full 
conformance with the International Council for Harmonisation E6 guideline for GCP and the principles of the Declaration of Helsinki or the laws and regulations of the country in which the 
research is conducted, whichever affords the grea ter protection to the patient. The study will also 
comply with the requirements of the Intern ational Council for Harmonisation E2A guideline 
(Clinical Safety Data Management: Definiti ons and Standards for Expedited Reporting). 
14.2. Institutional Review Board/Independent Ethics Committee 
This protocol, the ICFs, any information to be  given to the patient, and relevant supporting 
information must be submitted, reviewed, a nd approved by the IRB/IEC before the study is 
initiated. In addition, any patient recruitment materials must be approved by the IRB/IEC. Copies 
of the IEC/IRB correspondence and approval of the amended ICF/other information and the 
approved amended ICF/other in formation must be forwarded to the sponsor promptly. 
The principal investigator is responsible for providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, 
and procedures established by the IRB/IEC. Investigators are also responsible for promptly 
informing the IRB/IEC of any protocol amendments. In addition to the requirements for 
reporting all AEs to the sponsor, investigators must comply with requirements for reporting 
SAEs to the local health authority and IRB/IEC. Investigators may receive written 
Investigational New Drug Safety Reports or other safety-related communications from the 
sponsor. Investigators are responsible for ensuring that such reports are reviewed and processed 
in accordance with health authority requirements and the policies and procedures established by 
their IRB/IEC and archived in the site‚Äôs study file. 
14.2.1.  Protocol Amendments 
Any protocol amendments will be prepared by th e sponsor. All protocol modifications must be 
submitted to competent authorities according to local requirements and to the IRB/IEC together 
with, if applicable, a revised model ICF in accordance with local requirements. Written 
documentation from competent authorities (according to local requirements) and from the IRB/IEC and required site approval must be obt ained by the sponsor before changes can be 
implemented, except for changes necessary to eliminate an immediate hazard to patients or changes that involve logistical or administrative aspects only (eg, change in medical monitor or 
contact information). 
Information on any change in risk and/or change  in scope must be provided to patients already 
actively participating in the study, and they must read, understand, and sign each revised ICF 
confirming their willingness to remain in the study. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 67 14.3. Informed Consent 
The sponsor‚Äôs sample ICF will be provided to eac h site. If applicable, it  will be provided in a 
certified translation of the local language. The fi nal IRB/IEC-approved ICFs must be provided to 
the sponsor for health authority submission purposes according to local requirements. 
The ICFs must be signed and dated by the pa tient or the patient‚Äôs legally authorized 
representative before his or her participation in th e study. The case history or clinical records for 
each patient shall document the informed consent process and that written informed consent was 
obtained before participation in the study. 
The ICFs will be revised whenever there are changes to study procedures or when new 
information becomes available that may affect the willingness of the patient to participate. The final revised IRB/IEC-approved consent forms mu st be provided to the sponsor for health 
authority submission purposes. 
Patients must be re-consented to the most curren t version of the ICFs (or to a significant new 
information/findings addendum in accordance with applicable laws and IRB/IEC policy) during 
their participation in the study.  For any updated or revised ICFs, the case history or clinical 
records for each patient shall document the informed consent process and that written informed 
consent was obtained using the updated/revised IC Fs for continued participation in the study. 
A copy of each signed ICF must be provided to th e patient or the patient‚Äôs legally authorized 
representative. All signed and dated ICFs must remain in each patient‚Äôs study file or in the site file and must be available for veri fication by study monitors at any time. 
14.4. Patient and Data Confidentiality 
The principal investigator and sponsor will ma intain confidentiality and privacy standards by 
following applicable data privacy laws covering the collection, storage, transmission, and 
processing of patients‚Äô persona l and medical information. 
The principal investigator sha ll code the medical information obtained during the study with a 
unique patient identification numbe r assigned to each patient enrolle d in the study. This approach 
ensures that patients‚Äô names are not included in any data set transmitted to any sponsor location. 
Patient medical information obtained during this study is confidential and may only be disclosed 
to third parties as permitted by the signed ICF (or a separate authorization for the use and 
disclosure of personal health information that ha s been signed by the patient ), unless permitted or 
required by law. 
In the event of a breach of the confidentiality of a patient‚Äôs personal and me dical information, the 
principal investigator and sponsor, as appropriate , shall fulfill all medi ation steps and reporting 
obligations under applicab le data privacy laws. 
Medical information may be give n to a patient‚Äôs personal physicia n or other appropriate medical 
personnel responsible for the patient ‚Äôs welfare for treatment purposes. 
Data generated during this study must be available for inspection upon request by representatives 
of the United States Food and Drug Administr ation and all other nati onal and local health 
authorities; by sponsor monitors, representatives, and collaborators; and by the IRBs/IECs for 
each study site, as appropriate. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 68 The investigator must ensure that patients‚Äô anony mity will be strictly ma intained and that their 
identities are protected from unauthorized parties. The investigator agrees that all information 
received from the sponsor, including but not limited to the BGB-DXP593 Investigator‚Äôs 
Brochure , this protocol, eCRFs, the Investigationa l New Drug, and any other study information, 
remain the sole and exclusive property of the sponsor during the conduct of the study and 
thereafter. This information is not to be disclosed to any third party (except employees or agents directly involved in the conduct of the study or as required by law) without prior written consent 
from the sponsor. The investigator further agrees to take all reasonable precautions to prevent the 
disclosure by any employee or agent of the study site to any third party or otherwise into the 
public domain. 
If a written contract for the conduct of the study includes confidentiality pr ovisions inconsistent 
with this section is executed, that contract‚Äôs provisions shall apply to the extent they are 
inconsistent with this section. 
14.5. Financial Disclosure 
Investigators are required to provide the sponsor with sufficient accurate financial information in 
accordance with regulations to allow the sponsor to submit complete disclosu re or certification to 
the absence of certain financial interest of the clinical investigators and/or disclose those financial interests, as required, to the appropriate health authorities. This is intended to ensure 
financial interests and a rrangements of the clinical investigat ors with BeiGene that could affect 
reliability of data submitted to health authorities are identified and disclosed by the sponsor. 
Investigators are responsible for providing info rmation about their fina ncial interests before 
participation in the study and to update this information if any re levant changes occur during the 
study and for 1 year after completion of th e study (ie, last patient, last visit). 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 69 15. DATA HANDLING AND RECORD KEEPING 
15.1. Data Collection and Management Responsibilities 
15.1.1.  Data Entry in the Electronic Case Report Form 
All study-related data coll ected or received by the investigator or study team shall be promptly 
entered into the eCRFs. In no event should the entr y of the study data into the eCRF be later than 
what is stipulated in the site contract after the data is collected or received by the investigator or 
study team without prior communication with and approval by the sponsor. 
15.1.2.  Data Collection 
Data required by the protocol will be entered into an electronic data capture (EDC) system. 
Data collection in the eCRF should follow the in structions described in the eCRF Completion 
Guidelines. The investigator has ultimate res ponsibility for the collection and reporting of all 
clinical data entered in the eCRF. The e-signatu re of the investigator or designee must be 
provided in the EDC system to attest to its accuracy, authenticity, and completeness. 
Data contained in the eCRFs are the sole propert y of BeiGene and should not be made available 
in any form to third parties without written permission from BeiGene, except for authorized 
representatives of BeiGene or a ppropriate regulatory authorities. 
15.1.3.  Data Management/Coding 
All final patient data, both eCRF and external data (eg, laboratory data), collected according to 
the protocol will be stored by BeiGene at the end of the study. 
Standard procedures (including following data review guidelines , computerized validation to 
produce queries, and maintenance of an audit file that includes all databa se modifications) will 
be followed to support accurate data collection. Da ta will be reviewed for outliers, logic, data 
inconsistencies, and completeness. 
During the study, a study monitor will make site vi sits to review protocol compliance, compare 
eCRFs against individual patient‚Äôs medical record s, and ensure that the study is being conducted 
according to pertinent regulatory requirements. The eCRF entries will be verified with source documentation. The review of medical records 
will be performed in a manner to ensure that patient confidentiality is maintained. Checking the 
eCRFs for completeness, clarity, and cross-check ing with source documents is required to 
monitor the progress of the study. Direct access to source data is also required for inspections 
and audits, and will be carried out with due consideration to data protection and medical 
confidentiality. 
The AE verbatim descriptions (the investigator‚Äôs description from the eCRF) will be coded using 
MedDRA. AEs will be coded to MedDRA by the lowest level term, preferred term, and primary 
system organ class. Concomitant medications will be coded using the World Health Organization Drug Dictionary. Concomitant diseases/medical history will be coded using MedDRA. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 70 15.2. Study Records Retention 
The investigator must maintain adequate and accurate records to enable the conduct of the study 
to be fully documented and the study data to be  subsequently verified. These documents should 
be classified into at least 1 of the following 2 categories: 1) investigator‚Äôs study file and/or 
2) patient clinical source documents. 
The investigator‚Äôs study file will contain th e protocol/amendments, eCRF and query forms, 
IRB/IEC and governmental approval with correspo ndence, ICFs, drug records, staff curriculum 
vitae and authorization forms, and other appropriate documents and correspondence. 
Patient clinical source documents (usually defi ned by the project in advance to record key 
efficacy/safety parameters independent of the eCRFs) would include but not be limited to 
documents such as the following: patient hospita l/clinic records, physician‚Äôs and nurse‚Äôs notes, 
appointment book, original laboratory reports, EC G, electroencephalogram, x-ray, pathology and 
special assessment reports, consultant letters, screening and enrollment logs, etc. 
Following closure of the study, the investigator must maintain all study records in a safe and 
secure location. The records must be maintained to allow easy and timely retrieval, when needed 
(eg, audit or inspection), and, whenever feasible , to allow any subsequent  review of data in 
conjunction with assessment of the facility, s upporting systems, and personnel. Where permitted 
by local laws/regulations or institutional policy, some or all of these records can be maintained in a format other than hard copy (eg, microfiche, scanned, electronic); however, caution needs to be 
exercised before such action is taken. The inve stigator must ensure that all reproductions are 
legible, are a true and accurate copy of the original, and meet accessibility and retrieval standards, including regenerating a hard copy, if required. Furthermore, the investigator must 
ensure there is an acceptable backup of these reproductions and that an acceptable quality control 
process exists for making these reproductions. 
The sponsor will inform the investigator of the time period for retaining these records to comply 
with all applicable regulatory requirements. The minimum retention time will meet the strictest 
standard applicable to that study center fo r the study, as dictated by any institutional 
requirements, local laws or regulations, or the sponsor‚Äôs standards/procedures; otherwise, the 
retention period will default to 15 years. 
The investigator must notify the sponsor of any changes in the archival arrangements including 
but not limited to the following: archival at an off-site facility or transfer of ownership of or 
responsibility for the records in the event the investigator leaves the study center. 
If the investigator cannot guarantee this archiving requirement at the study site for any or all of 
the documents, special arrangements must be made between the investigator and BeiGene to 
store these in sealed containers outside of the site so that they can be returned sealed to the 
investigator in case of a regulatory audit. When source documents are required for the continued care of the patient, appropriate copies should be made for storage outside of the site. 
Biological samples at the conclusion of this study may be retained as outlined in the agreement 
with the CRO managing the biological samples, for th e shorter of a period of up to 10 years or as 
allowed by your IRB/IEC. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 71 15.3. Protocol Deviations 
The investigator is responsible for ensuring th at the study is conducted in accordance with the 
procedures and evaluations described in this prot ocol. Investigators assert they will apply due 
diligence to avoid protocol deviations and shall report all protocol deviations to the sponsor. 
The investigator is to document and explain any deviations from the approved protocol. The 
investigator must promptly report any major deviat ions that might impact patient safety and/or 
data integrity to the sponsor and to the IRB/IEC, in accordance with established IRB/IEC 
policies and procedures. 
15.4. Study Report and Publications 
A clinical study report will be prepared and provided to the regulatory agency(ies). BeiGene will 
ensure that the report meets the standards set out in the International Council for Harmonisation 
Guideline for Structure and Content of Clinical Study Reports (ICH E3). An abbreviated report may be prepared in certain cases. 
The results of this study will be published or presented at scientific meetings in a timely, 
objective, and clinically meani ngful manner that is consistent  with good science, industry and 
regulatory guidance, and the need to protect the intellectual property of the sponsor, regardless of 
the outcome of the study. The data generated in this clinical study are the exclusive property of 
the sponsor and are confidential. For a multicenter study, the first publication or disclosure of 
study results shall be a complete, joint multicenter publication, or disclosure coordinated by the 
sponsor. Thereafter, any secondary publications will reference the original publication(s). 
Authorship will be determined by mutual agreem ent and all authors must meet the criteria for 
authorship established by the International Committee of Medical Journal Editors Uniform 
Requirements for Manuscripts or stricter local criteria ( International Committee of Medical 
Journal Editors 2016 ). 
Each investigator agrees to submit all manus cripts, abstracts, posters, publications, and 
presentations (both oral and written) to the sponsor for review before submission or presentation 
in accordance with the clinical study agreement. Th is allows the sponsor to protect proprietary 
information, provide comments based on informat ion from other studies that may not yet be 
available to the investigator, and ensure scientific and clinical accuracy. The details of the processes of producing and reviewing reports, manu scripts, and presentations based on the data 
from this study will be presented in the investigato r‚Äôs clinical study agreement. Each investigator 
agrees that, in accordance with the terms of the clinical study agreement, a further delay of the 
publication/presentation may be requested by the sponsor to allow for patent filings and/or 
protection in advance of the publication/presentation. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 72 15.5. Study and Study Center Closure 
Upon completion of the study, the unblinded moni tor will conduct the following activities in 
conjunction with the investigator or study center personnel, as appropriate: 
x Return/provide all study data to the sponsor 
x Resolution and closure of all data queries 
x Accountability, reconciliation, and arrangements for unused study drug(s) 
x Review of study records for completeness 
x Collection of all study documents for the trial master file filing according to GCP and 
local regulation 
x Shipment of samples (including but not limited to those for PK, ADA, and biomarkers) to 
the assay laboratory for central laboratory analysis according to protocol and laboratory 
manual requirements 
In addition, the sponsor reserves the right to suspend the enrollment or prematurely discontinue 
this study either at a single study center or at all study centers at any time for any reason. Potential reasons for suspension or discontinuati on include but are not limited to: safety or 
ethical issues or noncompliance with this protoc ol, GCP, the sponsor‚Äôs written instructions, the 
clinical study agreement, or applicable laws an d regulations. If the sponsor determines such 
action is needed, the sponsor will discuss this with the investigator (including the reasons for 
taking such action) at that time. When feasible, the sponsor will provide advance notification to 
the investigator of the impending action before it takes effect. 
The sponsor will promptly inform all other inve stigators and/or institutions conducting the study 
if the study is suspended or terminated for safety reasons. The sponsor will also inform the 
regulatory authorities of the suspension or termination of the study and the reason(s) for the action. If required by applicable regulations, the investigator must inform the IEC/IRB promptly 
and provide the reason for the suspension or termination. 
If the study is prematurely discontinued, all study data must still be provided to the sponsor. In 
addition, arrangements will be made  for the return of all unused study drug(s) in accordance with 
the applicable sponsor procedures for the study. 
Financial compensation to the investigators and/or institutions will be in accordance with the 
clinical study agreement established between the i nvestigator and/or institutions and the sponsor. 
15.6. Information Disclosure and Inventions 
All rights, title, and interests in  any inventions, know-how, or other intellectual or industrial 
property rights that are conceived or reduced to practice by the study center personnel during the 
course of or as a result of the study are the sole property of the sponsor and are hereby assigned 
to the sponsor. 
If a written contract for the conduct of the study, which includes ownership provisions 
inconsistent with this statement, is executed between the sponsor and the study center, that 
contract‚Äôs ownership provisions shall apply rather than this statement. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 73 All information provided by the sponsor and all data and information ge nerated by the study 
center as part of the study (other than a patient‚Äôs medical records) are the sole property of the 
sponsor and will be kept confidential by the investigator and other study center personnel.  
This information and data will not be used by the investigator or other study center personnel for 
any purpose other than conducting the study withou t the prior written consent of the sponsor. 
These restrictions do not apply to: 
x Information that becomes publicly available th rough no fault of the investigator or study 
center personnel 
x Information that is necessary to disclose in confidence to an IEC/IRB solely for the 
evaluation of the study 
x Information that is necessary to disclose to provide appropriate medical care to a patient 
x Study results that may be publis hed as described in Section 15.4 
If a written contract for the conduct of the study, wh ich includes provisions inconsistent with this 
statement is executed, that contract‚Äôs provisions shall apply rather than this statement. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 74 16. REFERENCES 
Arvin AM, Fink K, Schmid MA, et al. A perspective on potential antibody-dependent 
enhancement of SARS-CoV-2. Nature. 2020;584(7821):353-63. 
BeiGene Investigator‚Äôs Brochure, BGB-DXP593. Edition 1.0, July 2020. 
Bryan A, Fink SL, Gattuso MA, et al. Anti-SAR S-CoV-2 IgG antibodies are associated with 
reduced viral load. medRxiv. Preprint posted online May 24, 2020. doi: 
10.1101/2020.05.22.20110551 
Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents 
rapid mutational escape seen with individual antibodies. Science. 2020;369(6506):1014-8. 
Cao YL, Su B, Guo XH, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by 
high-throughout single-cell sequencing of convale scent patients‚Äô B cells. Cell. 2020;182:1-12. 
Clinical Trials Facilitation Group (CTFG). Recommendations related to contraception and 
pregnancy testing in clinical  trials. September 15, 2014. 
http://www.hma.eu/fileadmin/dateien/Human_Medicines/01-
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf 
COVID-19 Treatment Guidelines Panel. Co ronavirus Disease 2019 (COVID-19) Treatment 
Guidelines. National Institutes of Health. Available at 
https://www.covid19treatmentguidelines .nih.gov/. Accessed 04 August 2020. 
Eigenmann MJ, Karlsen TV, Krippendorff BF, et al. Interstitial IgG antibody pharmacokinetics 
assessed by combined in vivo- and physio logically-based pharm acokinetic modelling 
approaches. J Physiol. 2017;595(24):7311-30. 
Fajnzylber J, Regan James, Coxen K, et al. SARS-CoV-2 viral load is associated with increased 
disease severity and mortality. Preprint posted online July 17, 2020; doi: 
10.1101/2020.07.15.20131789 
Hart TK, Cook RM, Zia-Amirhosseini P, et al. Preclinical efficacy and safety of mepolizumab 
(SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy 
Clin Immunol. 2001;108(2):250-7. 
Hershberger E, Sloan S, Narayan K, et al. Safety  and efficacy of monoclonal antibody VIS410 in 
adults with uncomplicated influenza A infection: Results from a randomized, double-blind, 
phase-2, placebo-controlled study. EBioMedicine. 2019;40:574-82.  
International Committee of Medical Journal Editors. Recommendations for the Conduct, 
Reporting, Editing, and Publication of Scholarly  Work in Medical Journals. 2016. Available 
online: http://www.icmje.org. Accessed 08 August 2017. Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: The reality and challenges. J 
Microbiol Immunol Infect. 2020;53:436-43. 
Joyner MJ, Bruno KA, Klassen SA, et al. Safety update: COVID-19 convalescent plasma in 
20,000 hospitalized patients. Mayo Clin Proc. 2020;95(9):1888-97. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 75 Khurshid Z, Zohaib S, Joshi C, et al. Saliva as  a non-invasive sample for the detection of SARS-
CoV-2: a systematic review. medRxiv. Preprint posted online May 13, 2020; doi: 
10.1101/2020.05.09.20096354 
Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike: evidence 
that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182(4):P812-27. Li Q, Wu J, Nie J, et al. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and 
Antigenicity. Cell. Preprint posted online July 17, 2020; doi.org/10.1016/j.cell.2020.07.012. 
Pujadas E, Chaudhry F, McBride R, et al. SARS-CoV-2 viral load predicts COVID-19 mortality. 
medRxiv. Preprint posted online June 12, 2020; doi: 10.1101/2020.06.11.20128934. 
Soar J, Pumphrey R, Cant A, et al. Emergency treatment of anaphylac tic reactions--guidelines 
for healthcare providers. Resuscitation. 2008;77(2):157-69. Shah DK, Betts AM. Antibody biodistribution coefficients: inferring tissue concentrations of 
monoclonal antibodies based on the plasma concen trations in several pr eclinical species and 
human. MAbs. 2013;5(2):297-305. 
Sullivan HC, Roback JD. Convalescent plasma: therapeutic hope or hopeless strategy in the 
SARS-CoV-2 pandemic. Transfus Med Rev. 2020;S0887-7963(20)30025-0. doi: 
10.1016/j.tmrv.2020.04.001. 
Tay MZ, Poh CM, R√©nia L, et al. The trinity of COVID-19: immunity, inflammation and 
intervention. Nat Rev Immunol. 2020;20:363-74. 
Walls AC, Park YJ, Tortorici MA, et al. Structure, Function, and Antigenicity of the SARS-
CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281-92.e6. 
Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, 
double-blind, placebo-controlled, multicen tre trial. Lancet. 2020;395(10236):1569-78. 
W√∂lfel R, Corman VM, Guggemos W, et al. Virol ogical assessment of hos pitalized patients with 
COVID-2019. Nature. 2020;581(7809),465-9. 
Zhou GY, Zhao Q. Perspectives on therapeutic neutralizing antibodies against the novel 
coronavirus SARS-CoV-2. Int J Biol Sci. 2020;16(10):1718-23. 
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbr eak associated with a new coronavirus of 
probable bat origin. Nature. 2020;579:1-4. 
 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 76 17. APPENDICES 
 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 79 b Telehealth/remote nurse home visits will be permitted after Day 1 visit (treatment)/discharge from the hospital if circumstance s prevent visits to the clinic. 
Day 5, Day 22, and Day 57 visits will be performed by phone/video. 
c The EOS Visit will be conducted within 7 days after a premature study discontinuation. The Day 113 visit is the EOS Visit for p atients who complete all the 
previously planned study visits. 
d The Safety Follow-up Visit is only for patients who prematurely discontinue the study within 30 days after study treatment. The  Safety Follow-up Visit will be 
conducted at 30 days (¬± 3 days) after study treatment (Day 31 [¬± 3 days]). If the premature discontinuation from study occurs w ithin 7 days prior to Day 31 
(¬± 3 days), the Safety Follow-up Visit can be combined with the EOS Visit or the Day 29 visit, as appropriate. 
e Written informed consent must be obtained before performing any study-specific procedures. Consent must be obtained using the c urrent version of the form 
approved by the Independent Ethics Committee (IEC)/Institutional Review Board (IRB). The consent can be obtained via remote con sent if approved by local 
IRB. 
f Follicle-stimulating hormone (FSH) and estradiol assessments will be performed in female patients who are < 55 years of age wit h no spontaneous menses for 
¬ï 12 months to identify the status of no childbearing potential (refer to Appendix 4). Historical test results are allowed. 
g Positive results of SARS-CoV-2 test (RT-PCR or other tests authorized by local regulatory authorities) ¬î 72 hours prior to screening are required for 
confirmation of eligibility. 
h Patients enrolled will be randomized via IRT to receive placebo, BGB-DXP593 5 mg/kg, BGB-DXP593 15 mg/kg, or BGB-DXP593 30 mg/k g on Day 1. 
i The dose of BGB-DXP593 will be based on the patient‚Äôs actual body weight on the day of receiving the study drug (Day 1). 
j Vital signs will be monitored approximately every 15 minutes during the infusion, and then hourly till 2 hours after the infusi on; the monitoring will include 
PHDVXUHPHQWVRIERG\WHPSHUDWXUH√õ&SXOVHUDWH respiratory rate, saturation of oxygen (SpO 2), and blood pressure (systolic and diastolic). Pulse rate and 
blood pressure will be measured while the patient is in a seated or supine position after resting for 10 minutes. Height will b e measured at screening only and 
weight will be measured at Day 1 before study drug dosing. 
k Complete physical examination includes evaluations of 1) head, eyes, ears, nose, and throat; 2) cardiovascular; 3) dermatologic al; 4) musculoskeletal; 
5) respiratory; 6) gastrointestinal; and 7) neurological systems.  
l At subsequent visits (and as clinically indicated), limited, symptom-directed physical examinations will be performed. 
m A 12-lead ECG will be performed at the timepoints specified in the table. All ECGs are to be obtained before other assessments scheduled at that same time 
HJYLWDOVLJQPHDVXUHPHQWVEORRGGUDZV7KHSDWLHQWVKRXOGUHVWLQDVHPLUHFXPEHQWRUVXSLQHSRVLWLRQIRU¬ïPLQXWHVLQ  the absence of environmental 
distractions that may induce changes in heart rate (eg, television, radio, conversation) before each ECG collection. 
n After informed consent has been signed but before the administration of the study drug, only serious adverse events (SAEs) shou ld be reported. After initiation 
of the study drug, all adverse events (AEs) and SAEs, regardless of relationship to study drug, will be reported until 30 days after study treatment or EOS Visit, 
whichever is later. After the period, the investigator should report any SAEs that are considered to be related to the study dr ug.  
o Refer to Section 8.3.2 for details regarding WHO 8-point ordinal scale. 
p The COVID-19-related symptoms include, but are not limited to, fever, cough, diarrhea, dizziness, rhinorrhea, anosmia, dysgeusia, sore throat, abdominal 
pain, anorexia, and vomiting. Refer to Section 8.3.3  for assessment of disease severity. 
q Local laboratory assessments of clinical chemistry, hematology, coagulation, and urinalysis will be conducted as outlined in Appendix 3. 
r laboratory tests (clinical chemistry, hematology, coagulation, urinalysis, and pregnancy test) performed within 3 days prior to screening visit can be used to confirm eligibility. 
s Urine pregnancy test using highly sensitive human chorionic gonadotropin will be performed in all women of childbearing potential at the specified timepoints. A confirmation serum pregnancy test must be performed if the urine pregnancy test is positive or equivocal. Serum pregnancy tests may be substituted for urine pregnancy tests if the site is not able to perform urine testing. Female patients with negative test results will be elig ible to receive the study drug. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 80 t Peripheral Blood samples will be collected from patients to explore the association of biomarkers with the efficacy of BGB-DXP5 93, including but not limited 
to SARS-CoV-2 serology, cytokines and gene expression signatures. Refer to the laboratory manual for instructions regarding sam ple collection, handling, 
labeling, storage, and shipping of laboratory samples.  
u Saliva samples collected here will also be used for SARS-CoV-2 mutation testing.  
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 82 APPENDIX 3.  CLINICAL LABORATORY ASSESSMENTS 
Clinical chemistry Hematology Coagulation Urinalysis 
Alkaline phosphatase 
Alanine aminotransferase Aspartate aminotransferase Albumin 
Total bilirubin 
Direct bilirubin 
Blood urea nitrogen or urea 
Potassium Sodium 
Total calcium
a 
Creatinine 
Glucose 
Lactate dehydrogenase 
Total protein 
Magnesium 
C-reactive protein Red blood cell count Hematocrit Hemoglobin Platelet count 
White blood cell count 
Lymphocyte count 
Neutrophil count Prothrombin time 
Partial thromboplastin 
time  or activated 
partial thromboplastin time 
International 
normalized ratio 
D-Dimers  Specific gravity pH Glucose Protein 
Blood 
Ketones 
Bilirubin 
Urobilinogen  Nitrite 
Leukocyte esterase or 
leukocyte 
Other Tests 
x Follicle-stimulating hormone (FSH) and estradiol test (as needed for female patients who are < 55 years of age ZLWKQRVSRQWDQHRXVPHQVHVIRU¬ïPRQWKVWRLGHQWLI\WKHVWDW XVRIQRFKLOGEHDULQJSRWHQWLDO  
x Highly sensitive human chorionic gonadotropin pregnancy test (in women of childbearing potential) 
x SARS-CoV-2 RT-qPCR test  
Abbreviations: SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; RT-qPCR, reverse transcription-quantitative polymerase chain reaction. 
a Total calcium values will be corrected for patients with hypoproteinemia. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 83 APPENDIX 4.  CONTRACEPTION GUIDELINES AND DEFINITIONS 
OF ‚ÄúWOMEN OF CHILDBEARING POTENTIAL,‚Äù ‚ÄúNO 
CHILDBEARING POTENTIAL‚Äù 
Contraception Guidelines 
The Clinical Trials Facilitation Group‚Äôs re commendations related to contraception and 
pregnancy testing in clinical trials include th e use of highly effective forms of birth control 
(Clinical Trials Facilitation Group 2014 ). These methods include the following: 
x Combined (estrogen- and progestogen-containing) hormonal contraception associated 
with the inhibition of ovulation 
 Oral, intravaginal, or transdermal 
x Progestogen-only hormonal contraception associ ated with the inhibition of ovulation: 
 Oral, injectable, or implantable  
Note: Oral birth control pills are not considered a highly effective form of birth 
control, and if they are selected, they must be used with a second, barrier method 
of contraception such as condoms with or without spermicide. 
x Intrauterine device 
x Intrauterine hormone-releasing system 
x Bilateral tubal occlusion 
x Vasectomized male partner 
Note: This is only considered a highly effective form of birth control when the vasectomized partner is the sole partner of the study participant and there has been a 
medical assessment confirming surgical success. 
 A sterile male is one for azoospermia has been demonstrated in a semen sample 
examination as definitive evidence of infertility. 
x Sexual abstinence (defined as refraining fro m heterosexual intercourse during the entire 
period of exposure associated with the study treatment).  NOTE: Total sexual abstinence should only be used as a contraceptive method if it is in 
line with the patient‚Äôs usual and preferred li festyle. Periodic abstinence (eg, calendar, 
ovulation, symptothermal, or postovulation me thods), declaration of abstinence for the 
duration of exposure to study drug(s), and w ithdrawal are not acceptable methods of 
contraception. 
Of note, barrier contraception (including male a nd female condoms with or without spermicide) 
is not considered a highly effective method of contraception and if used, this method must be 
combined with another accep table method listed above. 
Version .0 VV-CLIN-073998 1
BGB-DXP593-102   BeiGene 
Protocol Amendment 2.0 27 October 2020 
 
CONFIDENTIAL Page 84 Definitions of ‚ÄúWomen of Childbearing Poten tial,‚Äù ‚ÄúWomen of No Childbearing Potential‚Äù 
As defined in this protocol, ‚Äúwomen of chil dbearing potential‚Äù are fe male patients who are 
physiologically capable of becoming pregnant. 
Conversely, ‚Äúwomen of no childbearing potential‚Äù  are defined as female patients meeting any of 
the following criteria: 
x Surgically sterile (ie, through bilateral salpingectomy, bilateral oophorectomy, or 
hysterectomy) 
x Postmenopausal, defined as: 
 ¬ï 55 years of age with no spontaneous menses for ¬ï 12 months OR 
 < 55 years of age with no spontaneous menses for ¬ï 12 months AND with a 
postmenopausal follicle-stimu lating hormone (FSH) concentration > 30 IU/mL 
and all alternative medical causes for the lack of spontaneous menses for 
¬ï 12 months have been ruled out, such as polycystic ovarian syndrome, 
hyperprolactinemia, etc. 
If an FSH measurement is required to confir m postmenopausal state, concomitant use of 
hormonal contraception or hormonal repl acement therapy should be excluded. 
Adapted from Clinical Trials Facilitation Group 2014 . 
Version .0 VV-CLIN-073998 1